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ABSTRACT
Obstacles sometimes limit enrollment in randomized clinical trials of an exper-
imental product versus an active control, making it desirable to augment the ran-
domized control group with historical control groups. However, bias between control
groups with respect to the mean outcome could lead to spurious conclusions. Meth-
ods are necessary that allow for the combination of control groups while controlling
for bias.
Pocock (1976) developed a Bayesian test to address this need, but it requires sub-
jective specification of the variance of the bias between the randomized and historical
control groups and is designed to include only a single historical control group. In
the context of an actively controlled non-inferiority trial, we extend his method on
three fronts. First, we replace subjective specification of the variance of the bias with
empirically driven estimates. Second, we develop an adaptive design that re-powers
a trial based on an interim estimate of the variance of the bias using observed data.
Third, we modify the test to include multiple historical control groups.
When including a single historical control group, simulations show that the true
bias, if known, can be used in place of the variance of the bias, and that this estimate
iv
maintains Type I Error with no loss in power as compared to using the true variance
of the bias. Further, we show that using an empirical estimate of the bias to estimate
the variance of bias may result in moderately inflated Type I Error, but that using
a conservative estimate of the bias (the upper bound of a 90% confidence interval)
maintains Type I Error. Simulations also demonstrate that using an estimate of the
bias at the interim and conclusion provides designed power but may result in moder-
ately inflated Type I Error. Therefore, a conservative estimate of the bias should be
used at trial end when using this approach. Lastly, it is shown that if an adequate
number of multiple historical control groups are available, the modified test maintains
Type I Error when using bias estimates. These methods provide objective guidance
on parameter estimation, but further research is necessary in order to improve power.
v
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1Chapter 1: Introduction
Broadly speaking, the objective of this thesis is to increase the feasibility of using
historical data within clinical trials in order to reduce the cost and burden of patient
enrollment. To do this, I will explore and offer improvements to a Bayesian test
developed by Pocock (1976), which was designed to allow for the inclusion of historical
data into controlled randomized clinical trials. For reasons to be explained later, I
will focus on actively controlled non-inferiority trials, although the research is more
widely applicable. In this chapter, I will explain the difficulties surrounding the use
of historical data, familiarize the reader with Bayesian clinical trial methods and non-
inferiority trial design, introduce Pocock’s test, elucidate a weakness in this test, and
outline potential improvements to the test to be explored in the remaining chapters
of the thesis.
1.1 Bias: The Problem with Historical Data
The gold standard of clinical trial design for an experimental intervention requires
concurrent randomization of patients, usually into two groups, one experimental treat-
ment and one control. Under such conditions, any statistically significant difference
between the groups at the end of the trial is likely due to treatment, and is unlikely
due to confounding. In some cases, however, applying the gold standard is impos-
sible or inefficient. If funding is scarce, time is short, or if subjects willing to be
randomized to a control group (often due to lack of perceived equipoise in the minds
of the subjects, justified or not) are difficult to find, carrying out an upcoming clinical
trial with a complete randomized control group might not be feasible. Or, if a large
sample of subjects recently received the same control treatment in a trial run under
seemingly identical conditions, it might be inefficient to enroll an entirely new control
group. In such situations, one might want to use a historical control group (data from
a previous clinical trial) instead of a current randomized control group. The problem
2with historical data, however, is that it has the potential to confound the comparison
between the new treatment and the control. The historical control group might dif-
fer on baseline characteristics (demographics, medication schedules, clinical trends,
etc.), both measurable and un-measurable, from the experimental group, resulting in
a biased comparison. Therefore, when using historical data in a clinical trial of an
experimental product, assessment of confounding is critical.
One traditional epidemiological approach to address confounding is the applica-
tion of multivariable regression to adjust for potential confounding variables when
comparing the treatment to control. This method, however, has several drawbacks
enumerated below:
1. It cannot adjust for hidden or unmeasurable confounders. (e.g. attitudes of
patients of the current trial might be different than in the past, which could
alter outcome.)
2. If sample size is insufficient, then including a large number of potential con-
founders in the regression model yields unstable treatment effect estimates.
3. If the historical control patients and experimental treatment patients differ
greatly on one or more confounders, the regression adjustment results will be
difficult to interpret at best and unreliable at worst.
A second epidemiological approach to deal with confounding is with propensity
score adjustment. Defined as the conditional probability of treatment given a set of
covariates, a propensity score is a scalar summary of the covariates. Because it is
scalar, there is no theoretical limitation on the number of covariates one can use, as
is the case with multivariable regression. Using propensity score as a single covariate,
one can use matching, stratification, or covariance adjustment to obtain an estimate
of the treatment effect while controlling for a large number of covariates that might
3be related to treatment assignment (D’Agostino, 1998). While this is an improvement
over multivariable regression, it still suffers from the problems 1.) and 3.) listed for
multivariable regression.
A third approach used to lessen the likelihood or magnitude of confounding when
comparing an experimental treatment to a historical control is to use a historical
control group in tandem with a random control group. This dual control approach
allows for direct comparison between the random and historical control group, thereby
giving investigators an objective way to assess bias due to any confounders, both
measurable and unmeasurable, present in the historical data. Depending on the
magnitude of this bias, investigators can alter the weight given to historical control.
One advantage to this approach is that by focusing on the bias itself, and not the
reasons for the bias (the confounders), it is no longer necessary to adjust for the
confounders themselves. While this design does not completely eliminate the necessity
of the random control group, it may reduce its required size, thereby saving time,
money, and recruitment efforts.
Pocock (1976) developed an elegant Bayesian statistical test that works within
this dual control framework. Recognizing the risk of confounding, however, Pocock
states:
The acceptability of a historical control group requires that it meets the
following conditions:
1. Such a group must have received a precisely defined standard treat-
ment which must be the same as the treatment for the randomized
controls.
2. The group must have been part of a recent clinical study which con-
tained the same requirements for patient eligibility.
43. The methods of treatment evaluation must be the same.
4. The distributions of important patient characteristcs in the group
should be comparable with those in the new trial.
5. The previous study must have been performed in the same organi-
zation with largely the same clinical investigators.
6. There must be no other indications leading one to expect differing
results between the randomized and historical control groups.
Only if all these conditions are met can one safely use the historical control
group as part of a randomized trial. (1976, p.177)
Embedded in Pocock’s test is a mathematical mechanism, which I will later explain
in depth, that controls the weight given to the historical control group depending on
one’s subjective belief about the variability of the outcome across trials.
In order to make Pocock’s test a practical option, however, there remains a need
for a data driven approach to appropriately determine the weight applied to the
historical control group. The goal of this research is to make Pocock’s test a viable
option by meeting this need.
1.2 Background
In the previous section I present the problems that accompany the use of historical
data, and suggest Pocock’s test as a means to address them. In this section I lay
out the background necessary to understand and carry out Pocock’s dual control
Bayesian test in the context of a non-inferiority trial. I will start by explaining why
non-inferiority trial design is a logical space to use historical data. Following this,
I will introduce both frequentist and Bayesian methods used in a fully randomized
actively controlled non-inferiority clinical trial. Lastly, I will introduce Pocock’s test
and provide a real example of its application.
51.2.1 Why Non-inferiority Trials?
In the medical device industry, often companies want to introduce slightly modified
versions of a medical device already on the market. Therefore, it is common for similar
devices to be introduced over relatively short periods of time, resulting in a series of
clinical trials that are run proximate in time and circumstance. As such, Pocock’s
conditions required to use historical control groups are often met, making it a fertile
industry for the use of historical data. In addition, the actively controlled non-
inferiority trial design is common in this industry because it allows for expeditious
entry into the market by comparing the new device to a similar device that is already
FDA approved. For these reasons, although Pocock’s test is not specifically designed
in the context of non-inferiority trials, it is nonetheless particularly well suited to this
type of trial.
1.2.2 Non-inferiority Methods: Frequentist and Bayesian
When people think of a clinical trial, generally they think of a phase 3 superiority
trial with two randomized groups, a group receiving a new treatment and a group
receiving placebo. At the end of such a trial, the groups are compared and one
concludes that either the treatment is superior, or not, to the placebo. The null
hypothesis is that the new treatment is inferior or equivalent to placebo, and the
alternative hypothesis is that the new treatment is superior. Assuming higher values
of the outcome are increasingly deleterious, if we let µT be the true mean outcome of
the treatment group and µC be the true mean outcome of the placebo, we can state
the hypotheses mathematically as: H0 : µT − µC ≥ 0; H1 : µT − µC < 0.
An alternative trial design is an actively controlled non-inferiority trial, in which
the purpose is not to show the effectiveness of a new treatment relative to placebo,
but to show non-inferiority of a new treatment to current standard of care. Accept-
able equivalence is quantified by a non-inferiority margin δ, which is determined by
6experts as the minimum clinically important difference. The null hypothesis of a
non-inferiority trial is that treatment is inferior to current standard of care, and the
alternative is that treatment is not inferior to current standard of care, by a certain
non-inferiority margin δ. This set of hypotheses can be stated mathematically as:
H0 : µT − µC ≥ δ; H1 : µT − µC < δ. Once the hypotheses have been restated as
given, analysis can proceed in the usual manner.
Traditional Frequentist Analysis
With a continuous outcome, analyzing a non-inferiority trial with a frequentist
approach can be as simple as a straightforward t-test. Assuming variance is the same
across groups, t (with nT + nC − 2 degrees of freedom, where nT is the sample size of
the treatment group and nC is the sample size of the control group) can be calculated
with Equations 1.1, 1.2, and 1.3:
t =
(x¯T − x¯C)− δ
sTC
￿
1/nT + 1/nc
(1.1)
sTC =
￿
(nT − 1)s2T + (nC − 1)s2C
nT + nC − 2 (1.2)
s2X =
1
nX − 1
￿
(xi − x¯)2 (1.3)
If t < tcrit, where tcrit is negative, we would reject the null hypothesis and conclude
non-inferiority.
Non-Inferiority: Bayesian Analysis
The key difference between the frequentist and the Bayesian approach is that the
frequentist approach yields point estimates of parameters, often by maximizing the
likelihood function, while the Bayesian approach yields probability distributions of
the parameters. The benefit to using probability distributions over point estimates
7is that one can use prior beliefs about the parameters, or prior distributions, to
inform final probability distributions, or posterior distributions. More specifically,
the posterior distribution P (θ|y) of the parameter(s) θ is the result of a combination
of the following two components:
1. The prior distribution of parameter(s) based on apriori beliefs: π(θ)
2. The likelihood function based on observed data: f(y|θ)
The posterior distribution of the parameter(s) is calculated with Equation 1.4, and
can be simplified to Equation 1.5 because the denominator is a constant.
P (θ|y) = f(y|θ)π(θ)￿
θ f(y|θ)π(θ)dθ
(1.4)
P (θ|y) ∝ f(y|θ)π(θ) (1.5)
The selection of π(θ) is up to the investigators depending on prior beliefs about θ.
One could either make it a skeptical prior, making it more difficult to reject the null
hypothesis, or one could make it an optimistic prior, making the null hypothesis easier
to reject. In practice, often a range of priors is selected, showing the conclusions under
different prior assumptions.
One possible decision rule of the hypothesis test in the Bayesian framework is
intuitive. Suppose your hypotheses are: H0 : θ ≥ 5; H1 : θ < 5. Then a decision
rule at α = .05 might be: if P (θ|y < 5) > 0.95 then reject the null hypothesis; else
if P (θ|y < 5) ≤ 0.95 then do not reject the null hypothesis. We will use this form of
decision rule in the Bayesian example that follows and in the remainder of the thesis.
1.2.3 Non-inferiority Example
In order to crystalize the difference between the two approaches and illuminate
their application, I present a modified example adopted from lecture notes prepared by
8Doros (2011). Suppose investigators are comparing two blood pressure medications,
an old medication X to a new medication Y, and that they want to show Y is non-
inferior to X. Suppose the endpoint is systolic blood pressure (SBP) and the non-
inferiority δ is 5 mmHg. State the hypotheses as: H0 : µY −µX ≥ δ; H1 : µY −µX < δ.
Upon completion of the trial, the mean SBP in the group treated with X (µˆx = x¯) is
135 mmHg, the mean SBP in the group treated with Y (µˆy = y¯) is 137 mmHg, and
the pooled standard deviation spooled (see Equation 1.2) of SBP, assuming variance is
the same in each group, is 5. Let the sample size of each group be nX = nY = 50.
Frequentist Test
Using Equation 1.1, calculate t, where t = (137−135)−5
5
√
1/50+1/50
= −3. Compare the t
statistic to the one sided 95% critical tcrit value, with 98 degrees of freedom (−1.66).
Since −3 < −1.64, we would reject the null hypothesis that the treatment is inferior
to the control.
Bayesian Test
Assume the estimated mean SBP of each independently sampled group can be
approximated with normal distributions, where µj, σ2j , and nj are the mean, vari-
ance and sample size of group j, respectively, and that the sample means follow the
distributions µˆx = x¯ ∼
￿
µx,
σ2X
nX
￿
and µˆy = y¯ ∼
￿
µY ,
σ2Y
nY
￿
. Assuming these distri-
butions, the estimated treatment effect is µˆy − µˆx = θˆ, and its distribution can be
approximated with Equation 1.6.
θˆ = µˆy − µˆx ∼ N
￿
µY − µX , σ
2
Y
nY
+
σ2X
nX
￿
(1.6)
If we also assume that the variance of SBP is the same in each group, σ2Y = σ
2
X = σ
2,
and that nY = nX , then Equation 1.6 simplifies to θˆ ∼
￿
θ, 2σ
2
n
￿
, where σ2 can be
estimated with the pooled variance of the groups = s2pooled = 25, as was the case with
9the frequentist approach.
If we have a firm prior belief that Y is inferior to X, then we could choose a skeptical
prior distribution of θ. For example, if we think there is a 1% chance that drug Y is
non-inferior to drug X (θ < 5), then we could select as pessimistic uninformative prior
distribution of θ to be: π(θ) ∼ N(µθ = 12, σ2θ = 9), which gives a prior probability
of 0.01 that θ < 5. In order to make calculations more intuitive, Bayesians rewrite
the variance of the prior distribution into the following form: σ2θ =
2σˆ2
n0
= 9, where n0
represents the effective sample size of the prior information. In this case it would be
n0 = 2 ∗ 25/9 = 5.5.
Using this convention, the posterior distribution of θ given θˆ = 2 can be defined
with Equation 1.7.
θ|y ∼ N
￿
nθˆ + n0µ
n+ n0
,
2σˆ2
n+ n0
￿
= N
￿
50 ∗ 2 + 5.5 ∗ 12
50 + 5.5
,
2 ∗ 25
50 + 5.5
￿
= N(3, .9) (1.7)
Recall that the null hypothesis is that the treatment is inferior to control by some
margin δ, and that the hypotheses are: H0 : θ > δ; H1 : θ ≤ δ. Therefore, if the
posterior probability P (θ ≤ δ) > 0.95, then we reject the null hypothesis and non-
inferiority is concluded; otherwise if the posterior probability P (θ ≤ δ) ≤ 0.95, we
cannot reject the null hypothesis. Using the posterior distribution given θˆ = 2 in
Equation 1.7, the P (θ|y < δ) = 0.982, leading us to reject the null hypothesis despite
a pessimistic prior.
1.2.4 Pocock’s Dual Control Bayesian Test
Having explained posterior distributions and the Bayesian decision rule, I will now
introduce Pocock’s test. Pocock starts with the assumption that the observations
DT , DR, DH for each group come from random variables XT , XR and XH (where T
denotes the treatment group, R denotes the random control group, and H denotes
10
the historical control group), and that these random variables come from normal
distributions, each with their own mean and variance: XT ∼ N(µT , σ2T ), XR ∼
N(µR, σ2R), XH ∼ N(µH , σ2H). Further, he assumes a bias (denoted with γ) exists
between the random and historical control groups stemming from confounding, and
that this bias comes from a normal distribution with a mean of 0 and a variance σ2γ,
where bias is defined as: γ = µR − µH . Assuming non-informative uniform priors
along R(−∞,∞) for µT , µR, and µH , Pocock shows the posterior distribution of
(µT − µC) to be defined with Equations 1.8, 1.9, and 1.10.
µT − µC |DT , DR, DH ∼ N
￿
µˆT − µˆC , σˆ
2
T
nT
+
￿
1
σˆ2R/nR
+
1
σˆ2H/nH + σ
2
γ
￿−1￿
(1.8)
µˆC =
(µˆR +WµˆH)
1 +W
(1.9)
W =
σˆ2R/nR
σˆ2H/nH + σ
2
γ
(1.10)
Where:
1. W = the weight assigned to the historical control group.
2. µˆT = x¯T , µˆR = x¯R, µˆH = x¯H , the estimated mean outcomes of the treatment,
current control, and historical control groups, respectively.
3. σˆ2T , σˆ
2
R, σˆ
2
H = the estimated variance of the outcome for the treatment, current
control, and historical control groups, respectively (where σˆ2j =
1
(nj−1)
￿i=nj
i=1 (xj−
x¯j)2.
4. nT , nR, nH = the number of patients enrolled in the treatment, current control
and historical control groups, respectively.
5. DT , DR, DH = the data observed in the treatment, current control and historical
11
Table 1.1: ECMO Survival Counts
Treatment Survivals Deaths Total
Historical CMT (H) 2 11 13
Current Randomized CMT (R) 6 4 10
ECMO (T) 9 0 9
control groups, respectively.
1.2.5 An Application of Pocock’s Method: ECMO
For the purposes of illustration, I provide an example using real data originally
presented in ”Bayesian Approaches to Clinical Trials and Health-Care Evaluation”
by Speigelhalter, Abrams and Myles (2010). Speigelhalter et. al. present the test in
the setting of a superiority trial.
Ware (1989) presents background to the example. Prior to 1977, infants with per-
sistent pulmonary hypertension (PPHT) had a survival rate of less than 20%. In the
mid-80s a new treatment, extracorporeal membrane oxygenation (ECMO), appeared
to increase survival rate up to 80%, but sample sizes were small. Investigators planned
a randomized trial comparing ECMO to conventional medical therapy (CMT), but
considering the rarity of the condition, also wanted to use historical control data in
order to increase sample size. In the first phase of the trial, all 9 infants receiving
ECMO survived, whereas only 6 out of 10 infants receiving CMT survived. At this
point, investigators stopped randomizing for ethical reasons, and assigned ECMO to
all infants (Ware, 1989). For historical control data, investigators reviewed recent
cases of PPHT at surrounding hospitals and found that 11 out of 13 infants with
severe PPHT receiving CMT had died. The final counts of survivals and deaths in
each group are presented in Table 1.1.
Pocock’s test assumes the outcome follows a normal distribution. Therefore, in
this case, in order to apply Pocock’s test, we must convert the event outcome into a
continuous outcome with an approximately normal distribution. We accomplish this
12
Table 1.2: ECMO log(odds) Conversion
Treatment odds Log-odds (µˆ)
Variance
of log-odds
(σˆ2/n)
Historical CMT (H) 4.6 1.526 0.487
Current Randomized CMT (R) 0.69 -0.368 0.376
ECMO (T) 0.0526 -2.944 2.105
by converting events to the log-odds scale. Equations 1.11 and 1.12 convert events to
the log-odds scale, and the converted values are presented in Table 1.2. Note that in
order to avoid any undefined values, as would be the case with any counts of 0, 0.5 is
added to all counts.
log-odds of deathj = µˆj = log
￿
# of deathsj + 0.5
# of survivalsj + 0.5
￿
(1.11)
Var(log-odds of death)j =
σˆ2j
nj
=
1
# of deathsj + 0.5
+
1
# of survivalsj + 0.5
(1.12)
Once we have outcomes that are approximately normally distributed, we need to
select a value of σ2γ before applying Pocock’s test. Spiegelhalter et. al. (2004) suggest
the following approach. We start by assuming the odds ratio (OR) of death in the
historical control group compared to random control group has a 95% CI of (0.5, 2).
That is to say, we think it is likely the odds of dying in the historical control group
are no more than twice as much, and no less than half as much, as the odds of dying
in the random control group. We also assume that expected OR is 1.
Next, note that the log(OR) of death in the historical control group relative to
the random control group equals the log-odds of death in the historical control group
minus the log-odds of death in the current random control group (µH −µR), which is
our definition of the bias γ. Therefore, on the logodds scale, we can assume the bias
γ has a 95% confidence interval of [log(.5) = 0 − 1.96 ∗ σγ, log(2) = 0 + 1.96 ∗ σγ].
Using either side of the interval, we can solve for σ2γ to be 0.125. Inserting the values
13
Table 1.3: ECMO Sensitivity Results
Relative Bias Corresponding σ2γ P (θ|y < 0)
1 0 0.9873
1.1 0.0024 0.9872
1.5 0.0428 0.9863
2 0.1251 0.9845
4 0.5003 0.9778
8 1.1256 0.9706
16 2.0011 0.9650
10000 22.082 0.9513
in Table 1.2 for µˆj, σˆ2j/nj, and the selected value of σ
2
γ, into Equation 1.8 results in a
posterior distribution for (µT − µC) of N(−3.29, 2.33). Letting θ = (µT − µC), then
if θ < 0, ECMO is superior to the control. The hypotheses of this superiority trial
can be stated as: H0 : θ ≥ 0, H1 : θ < 0. Using the posterior distribution of θ to
be N(−3.29, 2.33), P (θ < 0) = .985, which is greater than 0.95. Therefore, using the
decision rule outline in Section 1.2.2, we reject the null hypothesis at the α = 0.05
level and conclude that ECMO is superior to the standard of care.
Note that to apply this test, we arbitrarily selected the factor of 2 to be the
realistic maximum OR between the historical and random control groups, which we
call the ”relative bias”. Table 1.3 shows a range of relative biases, their corresponding
values of σ2γ, and the resulting P (θ|y < 0) (Spiegelhalter et. al., 2004). It is clear from
this table that as you increase the relative bias, and therefore the value of σ2γ, the
probability that the θ < 0 steadily decreases. In all cases, however, P (θ < 0) > 0.95,
resulting in a consistent decision to reject the null hypothesis.
1.3 Simulations Applying Pocock’s Test
In the preceding example of Pocock’s test, σ2γ is subjectively specified. In a subset
of the simulations provided in this dissertation, I will show that misspecification of σ2γ
may lead to inflated Type I Error and reduce power in the setting of a non-inferiority
clinical trial.
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1.3.1 Details of the Simulations
When assessing Type I Error in a non-inferiority trial, observations of the treat-
ment group are drawn from the normal distribution N(µT = δ, σ2T = 1) (where δ is the
non-inferiority margin), and the observations of the random control group are drawn
from a standard normal distribution N(µR = 0, σ2R = 1). When assessing power, both
the treatment and the random control observations are drawn from standard normal
distributions. (Standard normal distributions were selected to maintain generality.)
To conform to Pocock’s assumptions, the bias of the historical control group γ is
drawn from the normal distribution N(0, σ2γ). Observations for the historical control
group are then drawn from the normal distribution N(γ, σ2H = 1).
Given these distributions, assuming no bias (which is equivalent to setting σ2γ = 0),
and a noninferiority δ = 0.249, the trial was powered to 80% using the statisti-
cal software package NCSS PASS version 08.0.6, generating the sample sizes nC =
(nR + nH) = 200 and nT = 200 (typical sample sizes within the device industry for
a continuous outcome). Further, I assumed nR = 100 and nH = 100, resulting in a
randomization treatment to control ratio of 2:1. I present results for two simulated
values of σ2γ (0 and 0.04), implying no bias and likely moderate bias, respectively.
For each scenario, I ran 100,000 simulations in order to give excellent asymptotic ap-
proximations. The simulation scenarios are explicitly summarized in Table 1.4. The
resulting Type I Error rates and corresponding power of applying Pocock’s test with
differing specified values of σ2γ are presented in Table 1.5.
When the true value of σ2γ is 0, σ
2
γ can only be either specified correctly or
over-specified. These simulations show that over-specification systematically reduces
power. When σ2γ is slightly over-specified, at 0.01, power is reduced to 0.756; when
there is significant over-specification (σ2γ=.64) power falls to 0.658. The effect of
over-specification of σ2γ on Type I Error is not as clear cut. When σ
2
γ is slightly over-
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Table 1.4: Mis-Specification Simulation Parameters
Bias
(γ) nT nR nH
Type I
Error:
Treat
Obs
Power:
Treat
Obs
Random
Obs
Historical
Obs δ
Theor-
etical
W
N(0,0) 200 100 100 N(δ, 1) N(0,1) N(0, 1) N(γ, 1) 0.249 1
N(0,0.04) 200 100 100 N(δ, 1) N(0, 1) N(0, 1) N(γ, 1) 0.249 0.2
specified at 0.01, Type I Error decreases from the nominal 0.05 to 0.042. However,
Type I Error gradually increases back to the nominal 0.05 as σ2γ is increasingly over-
specified. In all scenarios, over-specification of σ2γ keeps Type I Error near or below
the nominal α = .05.
In the case when the true value of σ2γ is 0.04, we see the problem of under-specifying
σ2γ. When σ
2
γ is incorrectly specified as 0, Type I Error reaches 0.123. When it is
slightly less under-specified at 0.01, Type I Error is 0.074. When σ2γ is properly spec-
ified, Type I Error is 0.051. In these simulations, under-specification of σ2γ yields
inflated Type I Error and over-specification yields decreased power (increased Type
II Error). In more extensive simulations provided in this dissertation, it is shown
that when σ2γ is properly specified, Pocock’s test maintains nominal α levels. It is
also to be shown that the test provides designed power when assuming the proper σ2γ
at the design stage. The results of the simulations show that if σ2γ could be specified
accurately, we could control Type I Error and benefit from additional sample size of
the historical control group.
1.4 Proposed Research
As he presents it, Pocock’s test requires a subjective specification σ2γ. He suggests
that if there are many (k > 5) multiple historical control groups available that one
might obtain an estimate of σ2γ based on a random effects model, but does not pursue
this avenue (1976). Further, he does not present a test that is able to use multiple
historical control groups. Therefore, I will explore applying a data driven estimate of
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Table 1.5: Mis-Specification Simulation Results
Simulated σ2γ
Specified
σ2γ
Type I
Error Power
Power
Using
only
Random
Controls
0 0 0.0513 0.8003 0.648
0.01 0.0420 0.7564
0.04 0.0437 0.7038
0.16 0.0479 0.6694
0.64 0.0499 0.6577
0.04 0 0.1229 0.7242 0.648
0.01 0.0740 0.7191
0.04 0.0511 0.6964
0.16 0.0487 0.6687
0.64 0.0501 0.6579
σ2γ when k ≤ 5 available in three situations:
1. when only a single historical control group is available;
2. in an adaptive trial design when only a single historical control group is available
with the goal of repowering the trial using an interim look at the data;
3. when multiple historical control groups are available (2 ≤ k ≤ 5).
A general description of each situation follows below.
1.4.1 Single Historical Control Group
In Chapter 3, I will make the argument that it is not necessary to know σ2γ per
se if the bias γ is known, and will confirm this empirically via simulation. This
realization allows us to specify σ2γ using an estimate of the bias, which is feasible with
a single historical control group. (Directly estimating σ2γ is not feasible with a single
historical control group). I will explore methods of estimating γ to find an estimate
that maintains nominal α levels, but still provides an increase in power.
17
1.4.2 Interim Adaptive Design with a Single Historical Control Group
In order to power a trial appropriately when applying Pocock’s method, a reason-
able apriori specification of σ2γ is required, but an accurate specification is unlikely
without any available data. Therefore, in Chapter 4 I will introduce an adaptive trial
design that takes an interim look at the data and recalculates the necessary sample
size of the randomized control group based on the methods of specifying σ2γ outlined
in Chapter 3. I will investigate the performance the proposed adaptive design in
terms of Type I Error and power via simulation analysis.
1.4.3 Multiple Historical Control Groups
In Chapter 5 I will adapt Pocock’s test to use a small number of historical control
groups (when k ≤ 5), and will explore data driven methods to specify σ2γ, both based
on those developed in Chapter 3 and those derived from using a sample variance of
the bias. Performance of these methods will also be assessed via simulation analysis.
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Chapter 2: Literature Review
The FDA’s reluctance to allow the use of historical data implies a dearth of sta-
tistical methods that adequately control for potential bias. If a method sufficiently
robust to bias were to exist, historical data could be used more often, thereby increas-
ing the pace of new treatments coming to market and reducing the cost of clinical
trials. I searched the literature to see if any procedures designed to use historical
data were ripe for improvement or extension.
2.1 The Literature
I reviewed 6 relevant papers and one text book. The methods reviewed include
both frequentist and Bayesian approaches, although Bayesian approaches are in the
preponderance.
2.2 Perspectives on the Use of Historical Data
A common theme seen throughout the literature is the acknowledgement that
the use of historical data is fraught with statistical peril. For instance, Dempster
et. al. comment that “Whether such historical data can and should be incorporated
into the statistical analysis is a difficult and controversial issue. It is clear that for
any randomized experiment, a test based on the randomization hypothesis is viewed
as desirable” (1983, p. 221). Striking a similar tone, Neuschwander et. al. write,
“The formal use of historical information in the analysis of a trial is controversial,
but might be justified on the grounds of efficiency” (2010, p. 6). Pocock articulates
the problem more specifically, writing that “with historical controls, one is unable to
ensure comparability between the groups of patients and methods for the new and
standard treatment. Obvious bias may occur if the investigator is selective in the
patients assigned to a new treatment . . . ” (1976, p. 175).
Due to the issue of potential bias, it is commonly suggested that the use of his-
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torical data is best suited for the “domain of toxicity or carcinogenicity testing in
animals” (Neuschwander et. al., 2010, p.6), where investigators have a high degree
of control of the conditions and large historical databases exist. Neuschwander et.
al. note, however, that while “the use of historical data in later phases of drug de-
velopment is less prevalent, . . .methods and examples have been discussed [Pocock’s
method]” (2010, p. 6). It is on this latter type of trial that I wish to focus, where
there are typically fewer historical control groups available. In the following section,
I will explain the various methods available and why I chose to focus on Pocock’s
approach.
2.3 The Methods
The method using propensity scores, a frequentist approach, as discussed in Chap-
ter 1 is relatively easy to implement. A propensity score is defined as the conditional
probability of treatment given a set of covariates, and as such is a scalar summary of
the measured covariates. Because the score is scalar, there is no theoretical limitation
on the number of covariates one can adjust for. The use of propensity scores is an
elegant extension of traditional regression methods used to control for confounders.
An advantage to the propensity score approach is that it can be applied in the case of
a single historical control group and across non-randomized experiments in general.
Another advantage is that it utilizes the entire sample size of the historical control
group, which is not necessarily the case with other methods to be described. As with
any regression based approach, however, the downside is that it does not account for
bias caused by unmeasured variables.
The remaining methods reviewed are all Bayesian and share a common thread;
they all attempt to assess the similarity across historical and concurrent control groups
and designate an appropriate weight to them accordingly. Neuenschwander et. al.
do an excellent job categorizing these approaches to incorporate historical data to
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estimate θ∗ into the five groups (2010, p7), where θ∗ is the parameter of interest in
the control group of the new trial:
1. Full equality. This would involve assuming θ1 = θ2 = . . . = θH =
θ∗, and essentially leads to a common-effects meta-analysis for the
historical control data which would then be pooled with future data
from the study being designed. [θi is the parameter of interest in
previous trial i, θ∗ is the parameter of interest in the new trial, and
the null hypothesis in a non-inferiority trial would be H0 = θT −θ∗ <
δ, assuming an increase in the outcome is deleterious.] This would
only seem justifiable under very tightly controlled situations.
2. Equal but discounted. This assumes the underlying parameters are
the same, but discounts the precision of the parameter in the histor-
ical trials. This is essentially the power prior approach [as presented
by Ibrahim and Chen], in which the likelihood for θh = θ∗ arising
from each past trial is taken to a power α between 0 and 1, which,
in exponential family models, is equivalent to shrinking the sample
size by a factor α. . . .
3. Biased. This model assumes that the past parameters are biased
versions of the current parameter, so that θh = θ∗ + γh and the bias
γh is assumed to have a distribution with, say, mean 0 and variance
σ2γ. Pocock’s early and insightful paper assumes σ
2
γ is specified us-
ing judgment, but mentions that it could be in principle estimated
from a random-effects model applied to multiple historical studies.
In general the bias model provides an explicit opportunity to make
judgments concerning the relevance and rigor of past studies and to
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express those judgments through an assumed distribution for γh.
4. Similar. This assumes that past and current studies are ’similar’ in
the sense that the parameters θ1, . . . , θh, θ∗ are assumed drawn from
a common distribution. [approach used by Dempster et. al.] . . .
5. Irrelevant. This is the simplest approach of all, in which historical
data is completely ignored.
Of these methods, Neuschwander et. al. comment that “methods 2-4 are mathemati-
cally similar, but that the bias model would allow inclusion of more historical studies
at a cost of additional judgmental input” (2010, p. 8). In other words, Pocock’s
test has a practical advantage in human clinical trials, where there are relatively
few historical control groups, but that this flexibility is accompanied by increased
subjectivity.
The method proposed by Ibrahim and Chen (2000) (”Equal but discounted”) is
currently popular, but is not simple to implement. Their model of ”Power Priors”
uses the likelihood function of the historical data raised the power α0 to define a prior
distribution for the parameters of the model as denoted by θ (see Equation 2.1).
π(θ|D0,α0) ∝ L(θ|D0)α0π0(θ|c0) (2.1)
Where:
1. α0 ranges from 0 and 1
2. c0 is a specified hyperparameter for the initial prior of θ
3. D0 is the historical data
4. θ is a vector of indexing parameters
22
π0(θ|c0) can be specified either as a proper or improper prior, and α0 is suggested
to be defined with a prior π0(α0|γ0) following a Beta distribution, where γ0 is a
specified hyperparameter vector. After specifying a prior for α0, the joint power prior
distribution for π(θ,α0|D0) is defined with Equation 2.2.
π(θ,α0|D0) ∝ L(θ|D0)α0π0(θ|c0)π(α0|γ0) (2.2)
By combining this joint prior with the likelihood function of the current trial using
the current data D, a joint posterior density distribution for (θ,α0) can be derived.
Using this posterior distribution, one can perform a likelihood ratio test based on
the marginal likelihoods of θ = 0 (the null hypothesis) and θ = θˆ (the estimated
parameter). The likelihoods would be obtained by integrating the joint posterior
density of (θ,α0) given θ = 0 and θ = θˆ, with respect to (θ,α0).
In essence, Ibrahim and Chen use α0 as a mechanism to designate a weight to
the historical data in an analogous fashion to the use of σ2γ in the Pocock model.
The method of power priors is more involved to implement methodologically and
computationally than Pocock’s model, requiring the specification priors for γ0 and c0,
and the use of Markov chain Monte Carlo (MCMC) methods. This method is most
appropriate when using a large number of tightly controlled historical control groups.
Dempster et. al. propose another Bayesian approach in which they assume a ran-
dom effects hierarchical model where all control groups, including the random control
group, come from the same superpopulation of control groups (1983) (”Similar”). In
particular, their model focuses on logistic regression in the context of dose response
trials, where historical control groups are often plentiful. Denoting event proportion
rates in controls for T + 1 experiments with p00, p10, p20, . . . , pT0, they assume the
control logits ν0, ν1, ..., νT to be independently normally distributed with mean µ and
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variance σ2 (see Equation 2.3).
νi = log[pi0/(1− pi0)] ∼ N(µ, σ2), for each control experiment i = 0, 1, ..., T (2.3)
In this model it is σ2, the variance of the control group logits, that implies the
weight given to the historical data. Within this framework, σ2 must be given a prior
distribution, which is somewhat subjective in its selection. In an acknowledgment
of this, as part of their analysis they perform a sensitivity analysis using different
prior distributions of σ2. While they find that the selection of the prior has little
effect on their results, they use a large number of historical control groups in their
examples (41 and 18), which give ample information on the variance of the control
group logits. It would be less practical to use this approach with few historical control
groups. Similar to the model of power priors, their approach is somewhat complex
and computationally intensive.
Pocock’s test (”Biased”) is a straightforward Bayesian method in which he replaces
post hoc approaches with a more objective and nuanced approach. Below is the
problem and the goal of his paper as he states it: (1976, p 176)
The main problem with this subjective interpretation of historical con-
trol groups with a randomized trial is that the researcher decides post
hoc whether to place any value in the historical data and he decides ar-
bitrarily how much this data should influence his conclusions. Thus, the
approach has been qualitative rather than quantitative. The objective of
this paper is to consider the combination of randomized and historical
control groups in a more quantitative manner so that formal methods of
statistical inference can be applied.
Similar to the other Bayesian approaches, he presents a formalized method to weight
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the historical data. In its current form, this test requires a subjective choice of σ2γ,
and as shown in Speigelhalter et. al. (2004, p 232), results are commonly presented
with an arbitrary range of values for σ2γ.
Pocock makes progress towards a more quantitative analysis, but the test as he
defines it remains somewhat subjective. Dempster et. al. opine that Pocock’s method
uses historical data in “an informal and subjective way” (1983, p. 221). Pocock’s
test, however, has several strengths: its ease of implementation methodologically and
computationally, and its flexibility to use fewer historical control groups.
2.4 Conclusions
The purpose of this review was to survey the statistical methods designed to tackle
the problem of using historical data in clinical trials and to identify a method that
might be improved upon or extended. Of the reviewed methods, Pocock’s test is
my preferred candidate for extension. Its focus on the degree of bias rather than on
the reasons for bias relieves it of the burden of measuring all potential confounders.
In addition, its relative ease of implementation, both methodologically and compu-
tationally, can only serve to increase the likelihood of adoption. Finally, it can be
implemented with very few historical control groups, making it a practical option for
human trials. All of these advantages could be more fully realized if we could move
the test away from the subjective and towards the objective.
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Chapter 3: Pocock’s Test: A Single Historical Control Group
In this chapter, I explore the application of Pocock’s test when only a single his-
torical control group is available for inclusion into an actively controlled randomized
non-inferiority clinical trial. I will propose the hypothesis that it is not necessary
to know σ2γ per se in order to maintain nominal Type I Error if you know the bias
(γ = µH − µR) and set σˆ2γ = γ2. Because it is significantly easier to estimate γ than
it is to estimate σ2γ, this finding could lead to a method that provides a quantitative,
as opposed to a subjective and qualitative, specification of σ2γ.
I will provide a heuristic argument for this hypothesis and then assess it via
simulation analysis. Convinced the hypothesis holds true using the true value of γ, I
will proceed to assess the performance of Pocock’s test using estimates of γˆ in place
of γ and setting σˆ2γ = γˆ
2. Finding an estimate of γ2 that maintains both Type I
Error and adequate power would achieve the goal of quantitatively and objectively
specifying σ2γ with a single historical control group, making Pocock’s test a viable
method to incorporate historical data into a randomized clinical trial.
3.1 A Word About Terminology: Estimates
In general, a population parameter is estimated based upon observable data. For
some of the estimates of σ2γ in this thesis, such as σˆ
2
γ = γ
2, we assume the bias of the
historical control groups (or the mean of the random control group) is an observable
value that we capture during simulation. The purpose of making this assumption is
to demonstrate the theoretical outcome that would result under ideal conditions. For
more practical estimates of σ2γ, we do not make these assumptions, and offer entirely
sampling driven approaches. In both cases we use the term estimate as the value
specified to σ2γ, even if we are using true population parameters to specify σ
2
γ. These
assumptions and terminology should be considered when assessing the performance
of each estimate for the remainder of the thesis.
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3.2 Using σˆ2γ = γ
2: A Thought Experiment
As showed in Section 1.2.4, Pocock’s method is predicated on specifying a value
for σ2γ, the variance of the bias between the historical and random control groups. In
the general case, the variance of a normal distribution with a known mean µ can be
unbiasedly estimated with Equation 3.1.
σˆ2 =
1
n
i=n￿
i=1
(x− µ)2 (3.1)
Therefore, estimating the variance of the bias with a single historical control group,
under the assumption of Pocock’s test that γ ∼ N(0, σ2γ), reduces to Equation 3.2.
σˆ2γ =
1
n
i=n￿
i=1
(γ − 0)2 = γ2 (3.2)
However, this estimate would have extremely poor precision with an n of 1, where n
is the number of historical control groups (often only one historical control group is
available). With such a poor estimate of σ2γ, there would be frequent underestimation
of σ2γ, which as demonstrated in section 1.3, results in inflated Type I Error (see
Table 1.5). Therefore, at first blush we might assume that using this estimate would
result in inflated Type I Error. Further consideration, however, might encourage us
to question this presumption.
I will put forth three hypothetical scenarios comparing the application of Pocock’s
test using of the true value of σ2γ versus using the estimate σˆ
2
γ = γ
2. For all scenarios
I assume σˆ2R = 1, σˆ
2
H = 1, nR = 100, nH = 100, and calculate the weight (W ) applied
to the historical control group using Equation 1.10, where a higher value ofW implies
more weight given to the historical control group. To put values of the bias γ into
context, assume in these scenarios that a clinical meaningful difference in outcome is
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2 units.
1. Scenario 1: Suppose the truth is that γ ∼ N(0, σ2γ = 10, 000). Assuming this
distribution, the bias has a 5% chance of being greater than 164, enormous
compared to a clinically meaningful difference. In fact, the probability that
the absolute bias is not of clinical significance P (−2 < γ < 2) is only 0.016.
Regardless of its likelihood, suppose that a randomly selected historical control
group from this distribution has no bias (γ = 0). In this case, if we were to
specify the true σ2γ = 10, 000 (W ≈ 0), we would discount the historical control
group almost entirely. Alternatively, if we were to use the estimate σˆ2γ = γ
2 = 0,
then W ≈ 1, thereby giving full weight to the historical control group. Given
there is no bias present, in this case it is more appropriate to fully weight the
historical control group than to completely discount it.
2. Scenario 2: Suppose the truth is that γ ∼ N(0, σ2γ = 2), and that a randomly
selected historical control group has a bias of γ = 5. In this case, if we were to
use the true value of σ2γ = 2, thenW = .005. Alternatively, if we were to use the
estimate σˆ2γ = γ
2 = 25, then W = .0004. Given the estimate σˆ2γ = γ
2 assigns a
lower weight to the historical data, and the fact that the bias is large relative
to clinical significance, using σˆ2γ = γ
2 seems to provide the more appropriate
specification of σ2γ.
3. Scenario 3: Suppose the truth is that γ ∼ N(0, σ2γ = 1), and that a randomly
selected historical control group has a bias of γ = 1. In this case, using the
estimate σˆ2γ = γ
2 and the true value of σ2γ yield the same W , making the two
methods equivalent.
In the first two scenarios, using the estimate of σˆ2γ = γ
2 designates the more ap-
propriate weight to the historical control group, and in the third they are equivalent.
28
Three specific situations are not sufficient to conclude that using the estimate σˆ2γ = γ
2
maintains nominal α levels, but they do suggest further investigation is warranted.
Therefore, I will test this hypothesis via simulation analysis.
3.3 Powering a Trial when Applying Pocock’s Test
Before detailing the specifics of the simulations and their results, it is necessary to
explain the method used to power them. To power a trial with Pocock’s test, using
Equation 1.10 for W , follow the steps below:
1. Power the trial with standard methods as if it were a randomized trial with
no historical control group, in order to calculate nT , the sample size of the
treatment group, and nC , the sample size of the control group.
2. Allow for the inclusion of a historical control group and let nC = nR+nH , where
nR is the sample size of the randomized control group, and nH is the sample
size of the historical control group. From nC and nH (nH is predetermined by
an existing dataset) calculate nR (nR = nC − nH).
3. Using apriori specifications of σ2H , σ
2
R, σ
2
γ, nR, and nH , calculate W .
4. Calculate the effective sample size of the control group (n￿C), where n
￿
C = nR +
W ∗ nH .
5. Calculate the number of additional subjects to enroll (nA) necessary to maintain
an effective sample size, where nA = nC - n￿C .
6. Update the size of the randomized control group to n￿R, where n
￿
R = nR + nA.
For example, in order to power one set of the simulations that are to follow, I assume
apriori that σ2C = 1, σ
2
T = 1, µT = 0, µC = 0, δ = .249, and powered the trial as if
it were fully randomized to 0.80 using the statistical software package NCSS PASS
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version 08.0.6, generating the sample sizes nT = 200 and nC = 200. Supposing further
that the historical control group is of size nH = 100 and that σ2γ = .01, I proceeded
through the steps above to yield a W of 0.5 and an n￿R = 150. Therefore, assuming
these parameter values, the final sample sizes necessary to power the trial to 0.80 are
nT = 200, n￿R = 150, nH = 100.
3.4 A Word About Power
By definition, power is the probability that the null hypothesis is rejected if the
null hypothesis is false. Ideally, to compare power across tests, the significance level is
identical. In the results that follow, I report power across tests that do not necessarily
maintain nominal Type I Error. This fact should be kept in mind during the discussion
of all simulation results, both in this chapter and in those that follow.
3.5 Simulation Details
Observations for the treatment, random control group, and historical control
groups are drawn from the distributions defined in Section 1.3 for Type I Error and
power simulation analysis. Assuming these distributions, trials were powered to 0.80
using the method defined in Section 3.3 assuming either σ2γ = 0 or σ
2
γ = 0.01.
To assess each method of specification of σ2γ in a variety of conditions, I altered
the variance of the bias (σ2γ) and the trial sizes (nT , nR, nH) (and the corresponding
non-inferiority margin δ to maintain consistent power). For each set of simulation
parameters I ran 100,000 simulations to obtain precise asymptotic results. More
specifically, the parameters were varied as follows:
1. σ2γ ranged from 0 to 0.64 (σ
2
γ ∈ 0, 0.01, 0.04, 0.16, 0.64)
2. trial sizes were:
(a) nT = 200, nR = 100, nH = 100: (.80 power assuming σ2γ = 0, δ = 0.249):
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Table 3.1: Single Historical Control Group: Simulation Parameters
Powered
assuming
Sim-
ulated
σ2γ nT nR nH
Type
I
Error:
Treat
Obs
Power:
Treat
Obs
Random
Obs
Hist-
orical
Obs δ
Theor-
etical
W
σ2γ = 0 0 200 100 100 N(δ, 1) N(0, 1) N(0, 1) N(γ, 1) 0.249 1.000
0.01 0.500
0.04 0.200
0.16 0.058
0.64 0.016
σ2γ = 0.01 0 200 150 100 N(δ, 1) N(0, 1) N(0, 1) N(γ, 1) 0.249 0.667
0.01 0.333
0.04 0.133
0.16 0.039
0.64 0.010
σ2γ = 0 0 500 250 250 N(δ, 1) N(0, 1) N(0, 1) N(γ, 1) 0.157 1.000
0.01 0.286
0.04 0.091
0.16 0.024
0.64 0.006
σ2γ = 0.01 0 500 429 250 N(δ, 1) N(0, 1) N(0, 1) N(γ, 1) 0.157 0.582
0.01 0.167
0.04 0.052
0.16 0.014
0.64 0.004
(b) nT = 200, nR = 150, nH = 100: (.80 power assuming σ2γ = 0.01, δ = 0.249):
(c) nT = 500, nR = 250, nH = 250: (.80 power assuming σ2γ = 0, δ = 0.157):
(d) nT = 500, nR = 429, nH = 250: (.80 power assuming σ2γ = 0.01, δ = 0.157):
Table 3.1 explicitly lists all of the simulation scenarios.
3.5.1 Simulation Results: Validating σ2γ
The results of the simulations applying Pocock’s test with the true value of σ2γ are
presented in Table 3.2. From this table we see that Type I Error maintains nominal
α levels for a wide range of simulated σ2γ values and in all trial sizes. When powered
to 0.80 assuming the true value of σ2γ, simulated power achieves theoretical power.
These results confirm empirically that Pocock’s test maintains nominal α levels when
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using the true value of σ2γ, and that the method of powering a trial using Pocock’s
test as devised in Section 3.3 achieves targeted power.
3.5.2 Simulation Results: Using σˆ2γ = γ
2
The simulation results when using the estimate σˆ2γ = γ
2 are also presented in
Table 3.2. In these results, we see that applying the estimate γ2 = σˆ2γ also maintains
Type I Error at the nominal α = .05 for a wide range of simulated σ2γ values and
across trial sizes. We also see that power reaches designed levels using this estimate.
Therefore, these simulations provide strong empirical support to the hypothesis that
knowing the true value of σ2γ is not necessary if you can estimate it with σˆ
2
γ = γ
2. This
observation is helpful because the bias (γ = µR − µH) is relatively easy to estimate
with just a single historical control group. In the following sections we will explore
the performance of Pocock’s test when we estimate γ itself and set σˆ2γ = γˆ
2.
3.6 Simulations Using σˆ2γ = γˆ
2
Thus far, I have confirmed that using the true value of σ2γ in Pocock’s test main-
tains nominal α levels and theoretical power. In addition, I have shown that using
σˆ2γ = γ
2 maintains nominal α levels while at the same time providing designed power.
Therefore, I will explore methods to estimate γ2 that is in turn used to estimate σ2γ.
Via simulation, I will show empirical Type I Error and power of five estimates of
γ2, which are presented in Table 3.3. In the first two, either the true value of the
mean of the historical control group, or the true value of the mean of the random
control group is assumed to be known. These estimates are γˆ21 = (µR−µˆH)2 and γˆ22 =
(µˆR − µH)2. In the latter three, both means are estimated from the data. These are
γˆ23 = (µˆR − µˆH)2, γˆ24 = max(|γˆ3 ± 1.64 ∗ SE(γˆ3)|)2, and γˆ25 = max(|γˆ3 ± SE(γˆ3)|)2. As
you will see, the estimates γˆ24 and γˆ
2
5 are conservatively large estimates of γ
2 designed
to maintain Type I Error.
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Table 3.2: Single Historical Control Group: Simulations Using σ2γ and σˆ
2
γ = γ
2
Powered
Assuming
Trial Size
nT :nR:nH δ
Simulated
σ2γ
Type I
Error
Using
σ2γ
Power
Using
σ2γ
Type I
Error
Using
σˆ2γ = γ
2
Power
Using
σˆ2γ = γ
2
σ2γ=0 200:100:100 .249 0 0.05020 0.80140 0.05020 0.80140
0.01 0.05002 0.74513 0.05026 0.76143
0.04 0.05060 0.69666 0.05083 0.72902
0.16 0.05071 0.66686 0.05069 0.70124
0.64 0.05061 0.65662 0.05126 0.68002
σ2γ=.01 200:150:100 .249 0 0.04972 0.83689 0.04972 0.83689
0.01 0.04953 0.80180 0.04957 0.81201
0.04 0.04991 0.77232 0.04989 0.79388
0.16 0.05003 0.75518 0.04985 0.77581
0.64 0.0499 0.7499 0.04965 0.76299
σ2γ=0 500:250:250 .157 0 0.05100 0.80034 0.05100 0.80034
0.01 0.05035 0.70995 0.05074 0.73947
0.04 0.05024 0.67254 0.05066 0.70839
0.16 0.04987 0.65775 0.0503 0.68444
0.64 0.05001 0.65294 0.04973 0.66968
σ2γ=01 500:429:250 .157 0 0.05046 0.84691 0.05046 0.84691
0.01 0.04951 0.80086 0.04952 0.81572
0.04 0.04993 0.78278 0.05025 0.80003
0.16 0.04988 0.77678 0.04984 0.78972
0.64 0.04959 0.77507 0.04959 0.78343
Table 3.3: Single Historical Control Group: Estimates of γ2
Notation Estimate
γˆ21 (µR − µˆH)2
γˆ22 (µˆR − µH)2
γˆ23 (µˆR − µˆH)2
γˆ24 max(|γˆ3 ± 1.64 ∗ SE(γˆ3)|)2
γˆ25 max(|γˆ3 ± 1 ∗ SE(γˆ3)|)2
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Naively, intuition might lead us to think that using γˆ21 and γˆ
2
2 would produce
similar rates of Type I Error and power, but simulations do not bear this out. In
Table 3.4, we see that using γˆ21 keeps Type I Error below the nominal α level of 0.05
in all scenarios, whereas using γˆ22 results in consistently inflated Type I Error, ranging
from 0.0533 to 0.0668. Not only is Type I Error lower when using γˆ21 , but in Table
3.5 we see that power is always greater when using γˆ21 for any given σ
2
γ. These results
show that knowing the true value of the mean of the random control group is more
important to the performance of Pocock’s test than knowing the true value of the
mean of the historical control group.
Both γˆ21 and γˆ
2
2 use a known value of either µR or µH , whereas γˆ
2
3 uses estimates
for both. As shown in Table 3.4, using γˆ23 results in inflated Type I Error, ranging
from 0.0522 to 0.062. In terms of power (see Table 3.5), using γˆ23 nearly reaches
designed levels when σ2γ = .01 (power=.7927, Type I Error=.0545), but falls short
when σ2γ = 0 (power=.7309, Type I Error=.0536). Regardless of power, in order to
maintain nominal α levels, γˆ23 needs to be modified, which leads us to γˆ
2
4 and γˆ
2
5 .
We have shown that using the true value of γ2 maintains type I Error but that
using the estimate γˆ23 does not. Presumably, this is due to systematic underestimation
of γ2. To reduce the likelihood of underestimating the γ2, we can use an upper bound
of the bias using confidence intervals. For instance, using a 90% confidence interval,
a conservative estimate can be stated mathematically as max(|γˆ3 ± 1.64 ∗ SE(γˆ3)|)2.
We see that this modification leads to Type I Error near nominal α levels (Table 3.4),
ranging from 0.049 to 0.052. This correction in Type I Error, however, comes at the
cost of a reduction in power (Table 3.5).
Less conservatively, we can use max(|γˆ3 ± 1 ∗ SE(γˆ3)|)2. With this estimate, Type
I Error (Table 3.4) remains close to nominal levels, with slight improvement in power
over γˆ24 (Table 3.5). For perspective, note that completely excluding the historical
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Table 3.4: Single Historical Control Group: Simulation Results - Type I Error
Powered
Assuming
Trial Size
nT :nR:nH δ σ2γ γˆ
2
1 γˆ
2
2 γˆ
2
3 γˆ
2
4 γˆ
2
5
σ2γ = 0 200:100:100 .249 0 0.03810 0.05470 0.05360 0.04960 0.04980
0.01 0.04030 0.06320 0.05750 0.05050 0.05140
0.04 0.04410 0.06680 0.06150 0.05150 0.05300
0.16 0.04740 0.06520 0.06200 0.05220 0.05360
0.64 0.04940 0.06070 0.05840 0.05240 0.05330
σ2γ = .01 200:150:100 .249 0 0.04170 0.05330 0.05220 0.04900 0.04940
0.01 0.04350 0.05890 0.05450 0.04970 0.05040
0.04 0.04550 0.06090 0.05680 0.05040 0.05103
0.16 0.04770 0.05910 0.05670 0.05080 0.05180
0.64 0.04880 0.05580 0.05480 0.05070 0.05150
σ2γ=0 500:250:250 .157 0 0.03878 0.05518 0.05347 0.04891 0.04982
0.01 0.04248 0.06610 0.05996 0.05024 0.05140
0.04 0.04551 0.06576 0.06175 0.05096 0.05280
0.16 0.04768 0.06116 0.05890 0.05126 0.05258
0.64 0.04841 0.05637 0.05551 0.05104 0.05162
σ2γ = .01 500:429:250 .157 0 0.04297 0.05264 0.05208 0.04925 0.04940
0.01 0.04515 0.05899 0.05497 0.05000 0.05027
0.04 0.04760 0.05868 0.05597 0.05064 0.05129
0.16 0.04835 0.05594 0.05436 0.05050 0.05136
0.64 0.04900 0.05333 0.05264 0.05040 0.05081
control group results in power of 0.648 when using the sample size when the study
was powered assuming σ2γ = 0, and is 0.744 when using the sample size when the
study assumed σ2γ = 0.01.
While the estimates γˆ24 and γˆ
2
5 make strides towards controlling Type I Error, they
come with the cost of a reduction in power. Of the scenarios presented, they boost
it by a maximum of 4.35 percent relative to the power achieved when completely
excluding the historical control group.
3.7 Conclusions
In the setting of a non-inferiority clinical trial, I have explored the performance
of Pocock’s test using a single historical control group in a variety of scenarios. I
verified that Pocock’s test works as is theoretically proposed when using the true
value of σ2γ. Further, I hypothesized that knowing the true value of the bias γ
2
35
Table 3.5: Single Historical Control Group: Simulation Results - Power
Powered
Assuming
Trial Size
nT :nR:nH δ σ2γ γˆ
2
1 γˆ
2
2 γˆ
2
3 γˆ
2
4 γˆ
2
5
σ2γ = 0 200:100:100 .249 0 0.7804 0.7561 0.7444 0.6754 0.6915
0.01 0.7607 0.7325 0.7306 0.6727 0.6864
0.04 0.7348 0.7070 0.7105 0.6686 0.6785
0.16 0.7055 0.6856 0.6870 0.6634 0.6690
0.64 0.6824 0.6704 0.6710 0.6589 0.6619
σ2γ = 0 200:150:100 .249 0 0.8256 0.8105 0.8026 0.7621 0.7713
0.01 0.8128 0.7931 0.7927 0.7602 0.7679
0.04 0.7970 0.7780 0.7798 0.7573 0.7632
0.16 0.7786 0.7637 0.7665 0.7540 0.7570
0.64 0.7652 0.7561 0.7573 0.7515 0.7530
σ2γ = 0.01 500:250:250 .157 0 0.7795 0.7542 0.7431 0.6746 0.6901
0.01 0.7427 0.7146 0.7149 0.6683 0.6791
0.04 0.7145 0.6907 0.6927 0.6634 0.6705
0.16 0.6881 0.6727 0.6746 0.6590 0.6625
0.64 0.6720 0.6632 0.6638 0.6557 0.6579
σ2γ = 0.01 500:429:250 .157 0 0.8376 0.8252 0.8189 0.7861 0.7937
0.01 0.8181 0.8003 0.8027 0.7829 0.7876
0.04 0.8037 0.7887 0.7913 0.7801 0.7829
0.16 0.7922 0.7823 0.7838 0.7774 0.7791
0.64 0.7844 0.7789 0.7792 0.7760 0.7769
would be sufficient in order to apply Pocock’s test and supported this argument with
empirical evidence. Finally, I tested the performance of Pocock’s test using a number
of estimates of γ2 with moderate success. Further investigation is required to find
a method of estimating of γ2 that would improve power, while maintaining nominal
Type I Error rates.
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Chapter 4: Pocock’s Test: An Adaptive Design
In Section 3.3 I introduced a straightforward method of powering a trial with
Pocock’s test assuming apriori knowledge of σ2γ. Through simulation, I demonstrated
that this method is effective at targeting the designed power of a trial if the known
value of σ2γ is used at the conclusion of the trial. Further, I showed that using the
known bias to specify σ2γ with γ
2 also achieves designed power while maintaining
nominal α levels. In the case of a single historical control group, however, there is no
estimate of either σ2γ or γ available at the beginning of a trial to be used in power
calculations. To address this problem, I will present an adaptive design method
that will use an interim look at the data to specify σ2γ using an estimate of the bias
(σ2γ = γˆ
2) at the interim. With this specified value of σ2γ, investigators can recalculate
the required sample size of the randomized control group. In the following sections I
will outline the adaptive design method in further detail and present simulations to
assess its efficacy.
4.1 Adaptive Design Method: The Details
One of the critical assumptions of Pocock’s test is that the bias in mean outcome
between the historical and random control groups comes from a N(0, σ2γ) distribution.
Therefore, if we were to assume a bias apriori, the most appropriate choice would
be 0, which is equivalent to assuming the historical control group comes from the
same population as the random control group. In the proposed method, I assume the
interim look occurs when half of the planned randomized control group have been
enrolled and their outcomes are observable. At this point of the trial, investigators
can estimate the bias between the random and the historical control groups, use this
observed bias to specify σ2γ, and calculate an adjusted sample size of the randomized
control group in order to achieve designed power under the assumption this is the
true σ2γ. The steps of the adaptive design are delineated below.
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1. Power the trial as if there is no anticipated bias between the random and his-
torical controls groups. This is equivalent to powering the trial as if it were
fully randomized, and setting the size of the pooled control group equal to the
sum of the random and historical control groups, or nC = nR + nH . Assuming
a 1:1 treatment to control ratio, the size of the treatment group equals the size
of the pooled control, or nT = nC .
2. Calculate the preliminary sample size of the randomized control group as the
difference between the pooled control group and the historical control group, or
nR = nC − nH .
3. Begin enrolling nT patients and nR patients using an appropriate randomization
ratio and scheme. When nR/2 samples have been enrolled and their outcomes
are observable, estimate the interim bias, setting γˆ = µˆH − µˆR, where µˆH is
sample mean of the historical control group and µˆR is the sample mean of the
random control group.
4. Specify σ2γ using an estimate of the bias γˆ, where σ
2
γ = γˆ
2.
5. Using interim estimates of the variance within each group (σˆ2H , σˆ
2
R), the estimate
of the variance of the bias (σˆ2γ), and original sample sizes nR and nH , calculate
W (the weight applied to the historical control group) using Equation 1.10.
6. Calculate the effective sample size (n￿C) of the pooled control group (nC), where
n￿C = nR +W ∗ nH .
7. Calculate the difference between the effective and the original sample size of the
pooled control group, where the difference is the number of additional subjects
necessary to enroll in the random control group (nA) in order to achieve designed
power, nA = nC - n￿C .
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8. Update the size of the randomized control group to n￿R, where n
￿
R = nR + nA.
9. Enroll the remaining patients in the treatment and random control groups,
where the remaining patients in the random control group is (n￿R − nR2 ). (Note
the sample size of the randomized treatment group does not change, and that
the randomization schedule and ratio will need to be adjusted should nA > 0.)
4.2 Simulation Analysis
Observations for the treatment, random control group, and historical control
groups are drawn from the distributions defined in Section 1.3 for both Type I Error
and power simulation analysis. Given these distributions, trials were preliminar-
ily powered to 0.80 using the method defined in Section 3.3 assuming σ2γ = 0 and
δ = .249. The goals of the simulation analyses were to:
1. confirm that specifying the true value of σ2γ at the interim and conclusion of the
trial provides predicted theoretical power and maintains Type I Error;
2. examine how the method performs in terms of Type I Error and power when
specifying σ2γ with γ
2 at the interim and conclusion of the trial;
3. examine how the method performs when using an estimate of the bias γˆ2 to
specify σ2γ at the interim and conclusion of the trial;
4. explore approaches to reduce the likelihood of underestimating γ2 when speci-
fying σ2γ with the estimate γˆ
2 at the conclusion of the trial.
With these goals in mind, simulations were conducted specifying σ2γ at the interim in
three ways:
1. with the true value of σ2γ;
2. with the true value of the bias (γ2);
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Table 4.1: Adaptive Design: Specifications of σ2γ
Specification Value
σ2γ1 0
σ2γ2 (µR − µH)2 = γ2
σ2γ3 (µˆR − µˆH)2 = γˆ2
σ2γ4 σ
2
γ
σ2γ5 (max(|γˆ ± 1.64 ∗ SE(γˆ)|)2
σ2γ6 (max(|γˆ ± SE(γˆ)|)2
Table 4.2: Adaptive Design: Simulation Parameters
Interim
Spec-
ification
of σ2γ
Sim-
ulated
σ2γ nT nR nH
Type I
Error:
Treat
Obs
Power:
Treat
Obs
Ran-
dom
Obs
Hist-
orical
Obs δ
Theor-
etical
apriori
W
σ2γ2 = γ
2 0 200 100 100 N(δ, 1) N(0, 1) N(0, 1) N(γ, 1) 0.249 1.000
0.01 0.500
0.04 0.200
0.16 0.058
0.64 0.016
σ2γ4 = σ
2
γ 0 200 100 100 N(δ, 1) N(0, 1) N(0, 1) N(γ, 1) 0.249 1.000
0.01 0.500
0.04 0.200
0.16 0.058
0.64 0.016
σ2γ3 = γˆ
2 0 200 100 100 N(δ, 1) N(0, 1) N(0, 1) N(γ, 1) 0.249 1.000
0.01 0.4500
0.04 0.200
0.16 0.058
0.64 0.016
3. with an estimate of the bias (γˆ2).
For each of these interim specifications, σ2γ is specified at the conclusion of the trial
with the values listed in Table 4.1, where σ2γ1 is for reference (implying no bias), and
σ2γ5 and σ
2
γ6 are modifications designed to reduce inflated Type I Error. Table 4.2
presents a detailed listing of all simulation scenarios.
4.2.1 Type I Error Results
The Type I Error results of the simulations are located in Table 4.3. If we assume
σ2γ = 0 (σ
2
γ1) when it in fact is greater than 0, we see sizable inflation of Type I
Error regardless of how σ2γ is specified at the interim, reaching up to 0.30 when the
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Table 4.3: Adaptive Design: Type I Error Results
Interim
Specification of
σ2γ
Simulated
σ2γ
Final
Spec.
σ2γ1
Final
Spec.
σ2γ2
Final
Spec.
σ2γ3
Final
Spec.
σ2γ4
Final
Spec.
σ2γ5
Final
Spec.
σ2γ6
σ2γ2 = γ
2 0 0.05022 0.05022 0.05211 0.05022 0.04782 0.04844
0.01 0.06416 0.05027 0.05524 0.04869 0.04988 0.05026
0.04 0.09584 0.05049 0.05651 0.04893 0.05016 0.05099
0.16 0.18062 0.05045 0.05554 0.04966 0.05040 0.05128
0.64 0.29972 0.05067 0.05383 0.04966 0.05026 0.05092
σ2γ4 = σ
2
γ 0 0.05022 0.05022 0.05211 0.05022 0.04782 0.04844
0.01 0.06473 0.04974 0.05439 0.04985 0.04949 0.05007
0.04 0.09685 0.04984 0.05517 0.04997 0.04980 0.05053
0.16 0.17945 0.05042 0.05511 0.05006 0.05056 0.05128
0.64 0.29787 0.05020 0.05303 0.05006 0.05027 0.05077
σ2γ3 = γˆ
2 0 0.04962 0.04962 0.05022 0.04962 0.04613 0.04678
0.01 0.06408 0.05017 0.05332 0.04963 0.04710 0.04824
0.04 0.09875 0.05152 0.05765 0.04993 0.04928 0.05050
0.16 0.18330 0.05154 0.05716 0.04959 0.05016 0.05141
0.64 0.30131 0.05112 0.05466 0.05004 0.05067 0.05153
simulated value of σ2γ = .64. We also see that specifying σ
2
γ with γ
2 (σ2γ2) at the end of
the trial yields nominal α levels regardless of how we specify σ2γ at the interim. Using
an estimate of the bias γˆ2 (σ2γ3) at the conclusion of the trial to specify σ
2
γ leads to
moderate inflation of Type I Error when σ2γ > 0, reaching up 0.057. When using the
true value of σ2γ (σ
2
γ4) at the conclusion of the trial, Type I Error is at or below nominal
α levels in all scenarios, empirically confirming the theory underpinning Pocock’s test.
In order to correct for the inflated Type I Error of σ2γ3 , one approach is to use a
conservative estimate of γ2, by setting γˆ2 = max(|γˆ± 1.64 ∗SE(γˆ)|)2. When applying
this estimate (σ2γ5) to specify σ
2
γ, Type I Error is kept at or below nominal α levels
in all scenarios, ranging from 0.0461 to 0.0507. Being somewhat less conservative, we
can set γˆ2 = max(|γˆ ± 1 ∗ SE(γˆ)|)2. Using this less conservative approach, Type I
Error ranges from 0.04678 to 0.05153.
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4.2.2 Power Results
Keeping in mind the note on power made in Section 3.4, the results of the power
simulations are presented in Table 4.4. If we assume σ2γ = 0 (σ
2
γ1), when it in fact
is greater than 0, we see sizable deflation in power regardless of the value of σ2γ used
at the interim, reaching as low as 0.63 when the simulated value of σ2γ = .64. In
contrast, using the true value of the bias γ2 to specify σ2γ (σ
2
γ2) at the end of the trial
yields designed power, ranging from 0.798 to 0.817, regardless of the specification of
σ2γ at the interim.
When using γˆ2 (σ2γ3) at the conclusion of the trial to specify σ
2
γ, there is moderate
loss of power in some scenarios if either the true value of σ2γ or the true value of γ
2 is
used to specify σ2γ at the interim, with power ranging from 0.743 to 0.807. However,
if we use an estimate of the bias γˆ2 to specify σ2γ at the interim and the conclusion,
power reaches close to the targeted level of 0.80, going only as low as 0.792. Specifying
the true value of σ2γ at the end of the trial (σ
2
γ4) yields mixed results depending on
how we specify σ2γ at the interim. If we specify the true value of σ
2
γ at the interim
and at the conclusion of trial, power consistently reaches 0.80. However, if we use
the true bias γ2 to specify σ2γ at the interim and use the true σ
2
γ at the conclusion,
then power ranges from 0.775 to 0.80. Using a highly conservative estimate of the
bias (σ2γ5) to specify σ
2
γ at the conclusion of the trial, power falls significantly short
of 0.80 at lower simulated values of σ2γ. Similarly, using a less conservative estimate
of the bias (σ2γ6) to specify σ
2
γ, power also falls short of 0.80 at lower simulated values
of σ2γ, although it’s somewhat improved over σ
2
γ5 .
In summary, three situations yield power consistently close to the designed 0.80:
1.) when we use the true bias γ2 (σ2γ2) to specify σ
2
γ both at the interim and conclusion
of the trial; 2.) when we use an estimate of the bias γˆ2 (σ2γ3) to specify σ
2
γ both at the
interim and conclusion of the trial (although this results in inflated Type I Error);
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Table 4.4: Adaptive Design: Power Results
Interim
Specification of
σ2γ
Simulated
σ2γ
Final
Spec.
σ2γ1
Final
Spec.
σ2γ2
Final
Spec.
σ2γ3
Final
Spec.
σ2γ4
Final
Spec.
σ2γ5
Final
Spec.
σ2γ6
σ2γ2 = γ
2 0 0.80008 0.80008 0.74373 0.80008 0.67421 0.69019
0.01 0.80549 0.80018 0.77402 0.78542 0.72999 0.74012
0.04 0.78016 0.80120 0.78364 0.77465 0.75803 0.76403
0.16 0.71213 0.80200 0.79122 0.77876 0.77755 0.78076
0.64 0.62794 0.80320 0.79679 0.78766 0.78947 0.79140
σ2γ4 = σ
2
γ 0 0.80008 0.80008 0.74373 0.80008 0.67421 0.69019
0.01 0.81535 0.81034 0.79140 0.80042 0.75760 0.76486
0.04 0.79504 0.81723 0.80683 0.80232 0.79030 0.79411
0.16 0.72472 0.81539 0.80831 0.80275 0.80108 0.80241
0.64 0.63607 0.81029 0.80537 0.80108 0.80156 0.80250
σ2γ3 = γˆ
2 0 0.83504 0.83504 0.80545 0.83504 0.75932 0.76944
0.01 0.81874 0.81303 0.79926 0.80321 0.76240 0.77072
0.04 0.78261 0.80143 0.79295 0.78169 0.76759 0.77394
0.16 0.71068 0.79829 0.79218 0.77946 0.77916 0.78234
0.64 0.62602 0.79997 0.79570 0.78742 0.78899 0.79087
and 3.) when we specify the true value of σ2γ (σ
2
γ4) both at the interim and conclusion
of the trial.
4.2.3 Sample Size Results
A critical goal of using historical data, and therefore Pocock’s method, is to min-
imize necessary recruitment into the randomized control group. Thus, beyond Type
I Error and power, it is important to report the resulting sample sizes of the ran-
domized control group using the adaptive design method. Statistics summarizing the
final sample sizes of the randomized control group are presented in Table 4.5. When
the true value of the bias γ2 (σ2γ2) is used at the interim to specify σ
2
γ, the mean n
￿
R
across the simulations ranges from 100 to 186 depending on the simulated value of
σ2γ. When the true value of σ
2
γ (σ
2
γ4) is specifed at the interim, the mean n
￿
R ranges
from 100 to 198. Interestingly, for all of the simulated values of σ2γ > 0, using the
true bias to specify σ2γ at the interim requires fewer randomized control subjects than
specifying the true σ2γ without any appreciable increase in Type I Error or loss in
power. When the estimated bias γˆ2 (σ2γ3) is used at the interim to specify σ
2
γ, the
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Figure 4.1: n￿R Density Distributions
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Table 4.5: Adaptive Design: Adjusted Randomized Control Sample Sizes (n￿R)
Interim
Specification of
σ2γ Simulated σ
2
γ Mean Min
25th
%tile Median
75th
%tile Max
σ2γ2 = γ
2 0 100 100 100 100 100 100
0.01 134.5 100 109 131 157 196
0.04 156.2 100 129 165 184 199
0.16 174.1 100 162 188 196 200
0.64 185.8 100 187 197 199 200
σ2γ4 = σ
2
γ 0 100 100 100 100 100 100
0.01 150.1 142 149 150 152 161
0.04 180.0 174 179 180 181 186
0.16 194.1 192 194 194 194 196
0.64 198.4 198 198 198 199 199
σ2γ3 = γˆ
2 0 151.9 100 124 158 180 198
0.01 156.3 100 129 165 184 199
0.04 164.1 100 142 176 190 199
0.16 175.8 100 166 190 196 200
0.64 186.1 100 187 197 199 200
mean n￿R ranges from 152 to 186.
Density plots of n￿R are presented in Figure 4.1, illustrating the differences in
distributions in n￿R depending on the specification of σ
2
γ at the interim. Specifying
the true σ2γ leads to a much narrower range of n
￿
R than using either the true bias or the
estimated bias. When the simulated value of σ2γ is small (.01), using an estimate of the
bias has noticeably more weight towards higher values of n￿R than using the true bias.
However, as σ2γ increases, the difference in n
￿
R between using the true and estimated
value of bias decreases and are virtually identical when σ2γ = .16 or σ
2
γ = .64.
In terms of sample size, specifying σ2γ using the true value of the bias γ
2 at the
interim is superior to using the true value of σ2γ. In addition, at smaller values of
simulated σ2γ, using an estimate of the bias γˆ
2 to specify σ2γ performs considerably
less well relative to using the true value of the bias γ2. At larger values of simulated
σ2γ, all 3 methods of specifying σ
2
γ yield similar sample sizes.
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Table 4.6: Power Gain Using σ2γ3 at the Interim and σ
2
γ6 at Conclusion
Simulated
σ2γ nT
Mean
n￿R
Power
Excluding
Historical
Control
Group
Power
Including
Historical
Control
Group
Gain
in
Power
0 200 152 0.746 0.769 0.023
0.01 200 156 0.752 0.771 0.019
0.04 200 164 0.762 0.774 0.012
0.16 200 176 0.776 0.782 0.006
0.64 200 186 0.787 0.79 0.003
4.3 Conclusions
In this chapter I have put forth an adaptive design method to power a trial using
historical data, Pocock’s test, and an interim look at the control data. I examined
the performance of this method in terms of Type I Error and power using a variety
ways of specifying σ2γ at the interim and conclusion of the trial. At the interim σ
2
γ was
specified in three ways: 1.) with the true value of σ2γ; 2.) with the true bias squared
(γ2); and 3.) with an estimate of the bias squared (γˆ2). At trial’s end, γˆ2 was
conservatively specified in two additional ways using a confidence interval approach
(see σ2γ5 and σ
2
γ6 from Table 4.1). From this investigation, the following conclusions
can be made:
1. Specifying σ2γ with its true value at the interim and conclusion achieves designed
power and maintains Type I Error, thereby confirming the underlying theory of
the adaptive design.
2. All three ways of specifying σ2γ at the interim control Type I Error only if either
the true value of σ2γ or γ
2 is used to specify σ2γ at trial end.
3. Using γ2 to specify σ2γ at the interim and end of trial maintains Type I Error,
yields designed power, and requires equal or smaller sample sizes than specifying
the true value of σ2γ. Thus, one does need to know the true σ
2
γ; knowing γ is
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sufficient and efficient, and γ2 should be used to specify σ2γ if γ is known.
4. In terms of practice, the most realistic approach is to use γˆ2 (σ2γ3) to specify
σ2γ at both the interim and final analysis. However, this does not fully control
Type I error unless σ2γ = 0, and therefore should be used with caution.
5. One may consider, again as a realistic approach, using γˆ2 (σ2γ3) at the interim
and one of the two conservative estimates of γˆ2 (σ2γ5 or σ
2
γ6) to specify σ
2
γ at the
trial’s conclusion. This approach controls Type I Error, but comes at the cost of
reduced power. The power benefit of this approach is summarized in Table 4.6,
which presents the resulting sample sizes, and the gain in power compared to
using the same sample nT and nR, but without including the historical control
data.
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Chapter 5: Pocock’s Test: Multiple Historical Control Groups
Chapter 3 focuses on the application of Pocock’s test with a single historical
control group. In this chapter, I assume there are 1 < k ≤ 5 historical control groups
available for combining with the randomized control group, and extend Pocock’s test
to include these multiple historical control groups. To do this, I redefine the parameter
estimates that are used within Pocock’s test. I start with the more basic parameters,
such as the means and variances of each group. Following that, I explore five methods
of specifying σ2γ using the multiple biases of the historical control groups. For each
method of estimating σ2γ, I assess the performance in terms of Type I Error and power
via simulation analysis.
5.1 Basic Parameter Estimation
Recall the posterior distribution of the treatment effect (µT − µC) is derived by
Pocock to be defined by Equations 1.8, 1.9, and 1.10 (see Section 1.2.4 for more
details). When multiple historical control groups are available, some parameters are
estimated in the same manner as when using a single historical control group, such
as µˆT and µˆR, but other parameters need to be redefined.
5.1.1 Estimating the Mean of the Historical Data
To estimate a single mean of the historical data µˆH from multiple historical control
groups, I used a weighted average as defined by Equation 5.1,
µˆH =
1
N
j=k￿
j=1
nHj ∗ µˆHj (5.1)
where k is the number of historical control groups, nHj is the sample size of historical
group j, N =
￿
nHj, and µˆHj = x¯Hj.
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5.1.2 Estimating the Outcome Variances within Groups
When estimating the variances of the groups, I assume the variance of the outcome
is the same in all groups, including each of the historical control groups, the treatment
group, and the randomized control group. Under this assumption, the variances
(σˆ2H = σˆ
2
R = σˆ
2
T ) are equal to the pooled sample variance as defined by Equations 5.2,
5.3, 5.4, and 5.5. In the case of non-inferiority trials, this is a reasonable assumption,
but it is suggested to test this assumption. If it is not valid, alternative methods of
estimating the variances should be considered.
σˆ2H = σˆ
2
R = σˆ
2
T =
￿i=nT
i=1 (xT i − x¯T )2 +
￿i=nR
i=1 (xRi − x¯R)2 + (nH − 1)σˆ2Hp
nT + nR + nH − 3 (5.2)
σˆ2Hp =
￿k
j=1(nHj − 1)s2j￿k
j=1(nHj − 1)
(5.3)
s2j =
1
nHj − 1
i=nHj￿
i=1
(xHij − x¯j)2 (5.4)
nH =
j=k￿
j=1
nHj (5.5)
5.2 Estimates for σ2γ
With the means of the groups and the variances within the groups defined and
estimated, σ2γ remains the only remaining parameter to define, and eventually esti-
mate. In general, if a random variable Z follows a normal distribution with mean
µ and variance σ2, and if µ is known, the variance of the distribution can be esti-
mated unbiasedly from a sample with the equation 1n
￿n
i=1(zi−µ)2 = σˆ2Z . Recall that
Pocock’s test assumes that the bias (γ = µH − µR) of each historical control group
comes from a normal distribution N(0, σ2γ). Therefore, with multiple historical con-
trol groups assuming the biases of each group are known, one can unbiasedly estimate
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the variance with Equation 5.6,
σˆ2γ =
1
k
k￿
j=1
(γHj − 0)2 =
￿
γ2Hj
k
(5.6)
where k is the number of historical control groups and γHj = (µHj − µR) is the true
bias present in historical control group Hj. I will use Equation 5.6 as a starting point
to generate five different methods of specifying σ2γ, and will proceed to assess their
performance in terms of Type I Error and power via simulation analysis.
5.2.1 Simulation Analysis
Observations for the random control group and experimental treatment group are
drawn from the distributions as defined in Section 1.3 for both Type I Error and
power analysis. To conform to Pocock’s assumptions, the bias of each historical con-
trol group γHj is drawn from the normal distribution N(0, σ2γ). After drawing γHj,
observations for each of k historical control groups are drawn from the normal distri-
bution N(γHj + µR, σ2H = 1), where µR = 0. To assess each method of specification
of σ2γ in a variety of scenarios, I altered the following parameters: the variance of the
bias (σ2γ), the number of historical control groups (k), and the trial size (nT , nR, nH)
(and the corresponding non-inferiority margin δ to maintain consistent power). To
examine how a more precise estimate of the bias would affect results, I increased the
size of the random control group for each general trial size (small, medium, and large),
holding all else held equal. I ran 100,000 simulations to obtain precise asymptotic
results in all scenarios. The parameters were varied as follows:
1. σ2γ ranged from 0 to 0.64 (σ
2
γ ∈ 0, 0.01, 0.04, 0.16, 0.64)
2. k ranged from 2 to 5;
3. trial size ranged from:
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Table 5.1: Multiple Historical Control Groups: Simulation Parameters
Sim-
ulated
σ2γ nT nR k nHj nH
Type I
Error:
Treat
Obs
Power:
Treat
Obs
Ran-
dom
Obs
Hist-
orical
Obs δ
Theor-
etical
W*
0 100 50 2 25 50 N(δ, 1) N(0, 1) N(0, 1) N(γHj , 1) 0.352 1.000
3 16 48
4 12 48
5 10 50
0.01 100 50 2 25 50 N(δ, 1) N(0, 1) N(0, 1) N(γHj , 1) 0.352 0.667
3 16 48
4 12 48
5 10 50
0.04 100 50 2 25 50 N(δ, 1) N(0, 1) N(0, 1) N(γHj , 1) 0.352 0.333
3 16 48
4 12 48
5 10 50
0.16 100 50 2 25 50 N(δ, 1) N(0, 1) N(0, 1) N(γHj , 1) 0.352 0.111
3 16 48
4 12 48
5 10 50
0.64 100 50 2 25 50 N(δ, 1) N(0, 1) N(0, 1) N(γHj , 1) 0.352 0.030
3 16 48
4 12 48
5 10 50
*Assuming a single historical control group.
(a) small: nT = 100, nR = 50, nH = 50, (.80 power if σ2γ = 0, δ = 0.352)
(b) medium: nT = 200, nR = 100, nH = 100, (.80 power if σ2γ = 0, δ = 0.249)
(c) large: nT = 500, nR = 250, nH = 250, (.80 power if σ2γ = 0, δ = 0.157)
4. the size of the random control group nR was increased for each trial size:
(a) small: nT = 100, nR = 75, nH = 50, (.834 power if σ2γ = 0, δ = 0.352)
(b) medium: nT = 200, nR = 150, nH = 100, (.835 power if σ2γ = 0, δ = 0.249)
(c) large: nT = 500, nR = 375, nH = 250, (.834 power if σ2γ = 0, δ = 0.157)
Table 5.1 explicitly lays out all of the scenarios for the trials of size nT = 100, nR = 50,
nH = 50. The same sets of simulations were run for each of the other trial sizes.
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Table 5.2: Multiple Historical Control Groups: Theoretical W’s*
Simulated σ2γ nT nR nH δ Theoretical W
0 100 50 50 0.352 1.000
0.01 0.667
0.04 0.333
0.16 0.111
0.64 0.030
0 100 75 50 0.352 0.666
0.01 0.444
0.04 0.222
0.16 0.074
0.64 0.020
0 200 100 100 0.249 1.000
0.01 0.500
0.04 0.200
0.16 0.058
0.64 0.016
0 200 150 100 0.249 0.667
0.01 0.333
0.04 0.133
0.16 0.040
0.64 0.010
0 500 250 250 0.157 1.000
0.01 0.285
0.04 0.091
0.16 0.024
0.64 0.006
0 500 375 250 0.157 0.666
0.01 0.190
0.04 0.061
0.16 0.016
0.64 0.004
*Assuming a single historical control group.
Estimate 1: σˆ2γ1 =
1
k
￿
γ2Hi
The sample variance of the true biases is defined by Equation 5.7, where γHj =
µHi − µR.
σˆ2γ1 =
1
k
￿
γ2Hi (5.7)
With this estimate, Type I Error rates are maintained at or below the nominal α = .05
levels for all scenarios, as shown in Figure 5.1:A. For each combination of k and trial
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Figure 5.1: Simulation Results Estimate 1
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size, Type I Error follows a U or J shape as σ2γ increases, with Type I Error ranging
from 0.044 to 0.052. (For full set of Type I Error results see Appendix Tables A.1,A.2,
A.3, A.4, A.5, and A.6.) In Figure 5.1 C, we see that holding all else equal, increasing
nR pushes Type I Error towards nominal α levels, and results in a shallower U shape.
In terms of power, as shown in Figure 5.1 B, for all combinations of k and trial
size, power levels are at the targeted level of 0.80 if simulated σ2γ = 0. (For full set of
Power results, for all estimates, see Appendix Tables A.7, A.8, A.9, A.10, A.12, and
A.11). As expected, power steadily declines in all scenarios as σ2γ increases. If σ
2
γ > 0
and is held constant, power decreases as trial size increases and the corresponding δ
decreases, which is the logical result if you consider that σ2γ is getting larger relative
to δ. Counterintuitively, power is highest when k = 2, if sample size and σ2γ are held
constant and σ2γ > 0.
Estimate 2: σˆ2γ2 = Var(γˆ)
The sample variance of the bias estimates is defined by Equation 5.8, where γˆHj =
µˆHi − µˆR.
σˆ2γ2 = V ar(γˆ) =
1
k − 1
j=k￿
j=1
(γˆj − ¯ˆγ)2 (5.8)
For this estimate, Type I Error rates are well below the nominal α = .05 levels when
σ2γ = 0 for all combinations of k and trial size (see Figure 5.2 A). As σ
2
γ increases,
however, Type I Error steadily increases for all combinations of k and trial size. If k
is large enough (k = 5), Type I Error is maintained at the nominal level of α = .05 for
all values of σ2γ (ranging from 0.043 to 0.051). Therefore, in juxtaposition to Estimate
1, Estimate 2 benefits from having more historical control groups. In Figure 5.2 C,
we see that for the medium size trial holding all else equal, increasing nR results in
Type I Errors moving towards the nominal α levels.
In terms of power (keeping in mind the inflated Type I Error at higher levels of σ2γ)
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Figure 5.2: Simulation Results Estimate 2
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several trends emerge from Figure 5.2 B. At lower values of σ2γ, power is significantly
higher if k is smaller, holding all else equal. Also, as with Estimate 1, increasing trial
size with the corresponding decrease in the non-inferiority δ marginally decreases
power if σ2γ > 0.
Estimate 3: σˆ2γ3 = (
1
N
￿j=k
j=1 (nHj ∗ µHj)− µR)2
Neither Estimate 1 nor Estimate 2 perform as ideally as using a single true bias
to specify σ2γ (γ
2) in the case of single historical control group, where nominal Type I
Error is maintained and power reaches or surpasses targeted levels (see section 3.5.2).
Therefore, in the case of multiple historical control groups, it may be desirable to
generate a single bias γ and specify σˆ2γ = γ
2. The most straightforward way to do
this is with a weighted mean of the historical control groups as defined by Equation
5.11 in order to create a pooled bias as defined by Equation 5.10. The weighted mean
bias can then be used to specify σ2γ as defined by Equation 5.9.
σˆ2γ3 = γp
2 (5.9)
γp = µHp − µR (5.10)
µHp =
1
N
j=k￿
j=1
(nHj ∗ µHj) (5.11)
Note that we are assuming the biases are known. From Figure 5.3 A we see that this
estimate maintains nominal Type I Error of α = .05, ranging from 0.050 to 0.052,
across all scenarios. As shown in Figure 5.3 C, increasing the size of the random
control group, holding all else equal, has little effect on Type I Error. In terms of
power (see Figure 5.3 B), the targeted value of 0.80 is reached in all scenarios when
σ2γ = 0. As with the other estimates, all else held equal, power is higher with a smaller
sample size and a correspondingly larger non-inferiority δ if σ2γ > 0. Power is also
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Figure 5.3: Simulation Results Estimate 3
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higher, holding trial size equal, as k increases if σ2γ > 0, thereby benefitting from a
higher value of k.
Estimate 4: σˆ2γ4 = (
1
N
￿j=k
j=1 (nHj ∗ µˆHj)− µˆR)2
Instead of using the true weighted mean of the historical control groups to generate
a single bias as we did with Estimate 3, for a more practical estimate we can create
an estimated weighted mean and single bias, as defined by Equations 5.14 and 5.13,
respectively. With these estimates, σ2γ can be specified with Equation 5.12.
σˆ2γ4 = γˆ
2
p (5.12)
γˆp = µˆHp − µˆR (5.13)
µˆHp =
1
N
j=k￿
j=1
(nHj ∗ µˆHj) (5.14)
Type I Error is modestly inflated with this estimate, ranging from 0.055 to 0.061 (see
Figure 5.4 A). Generally speaking, Type I Error increases as σ2γ increases, although
it follows an upside down U shape when trial size is large (nT = 500, nR = 250,
nH = 250). Holding all other variables constant, increasing k appears to have minimal
effect on Type I Error. Increasing the size of nR, all else equal, brings Type I Error
closer to nominal levels (see Figure 5.4 C).
In terms of power, from Figure 5.4 B we see that the power of this estimate never
reaches 0.80, is effectively unchanged with higher values of k, and is marginally higher
with a smaller trial and a correspondingly larger non-inferiority δ, all else held equal.
Estimate 5: Pooling All Historical Data into a Single Group
For the sake of reference, it is of interest to see how all of these estimates compare
to pooling all historical observations into a single group, and specifying σˆ2γ = γˆ
2.
While the effect of this pooling has no impact on the specification of σ2γ relative to
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Figure 5.4: Simulation Results Estimate 4
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Figure 5.5: Simulation Results Estimate 5
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Estimate 4, it does impact the estimates of the variances. Instead of calculating
the pooled historical control group variance as in Equation 5.3, it is calculated with
Equation 5.15.
σˆ2Hp =
j=k￿
j=1
i=nHi￿
i=1
(xHij − x¯j)2 (5.15)
Similar to Estimate 4, Estimate 5 generally results in inflated Type I Error across
all combinations of k and trial size, ranging from 0.05 to 0.06, with an upside down
U shape depending on σ2γ (see Figure 5.5: A). In general, relative to Estimate 4,
Estimate 5 results in slightly lower inflation of Type I Error.
The power reached with Estimate 5 never reaches 0.75, and as with all other
estimates, drops steadily with higher values of σ2γ. Generally speaking, compared to
Estimate 4, Estimate 5 has slightly lower power across scenarios, but due to its better
control of Type I Error is the preferable estimate of the two.
5.3 Conclusions
In this chapter I presented an extension of Pocock’s test to include multiple his-
torical control groups and examined several methods to specify σ2γ in this context. I
investigated the performance of these methods in terms of Type I Error and power
via simulation analysis and concluded the following:
1. Using a pooled bias γ2p (Estimate 3) to specify σ
2
γ maintains Type I Error and
yields designed power. Thus, one does not need to know the true σ2γ; knowing
the pooled bias is sufficient and efficient, and therefore can be used in place of
σ2γ, if σ
2
γ is unknown.
2. If σ2γ = 0, Estimates 1, 2 and 3 maintain nominal α levels, but only Estimates
1 and 3 provide designed power.
3. In terms of practice, Estimate 2 is the most realistic approach (it requires no
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Table 5.3: Number of Historical Control Groups Necessary to Reach Nominal Type I Error
Simulated
σ2γ
nT = 100
nR = 50
nH = 50
k (Power gain)
nT = 200
nR = 100
nH = 100
k (Power gain)
nT = 500
nR = 250
nH = 250
k (Power gain)
0 2 (.11) 2 (.10) 2 (.10)
0.01 2 (.10) 2 (.09) 3 (.06)
0.04 3 (.07) 3 (.05) 3 (.036)
0.16 4 (.038) 4 (.024) 4 (.014)
0.64 5 (.019) 4 (.009) 4 (.006)
known parameters) and maintains Type I Error if k is large enough. Table
5.3 presents the number of historical control groups necessary to reach nominal
α levels for each value of σ2γ and the corresponding gain in power relative to
excluding historical data entirely.
4. If k is small, Estimate 5 is an alternative realistic approach (requiring no known
parameters) that can be used, but it comes with some inflation in Type I Error,
and therefore should be used with caution.
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Chapter 6: Conclusion
Despite all of the methods available to incorporate historical data into clinical
trials, there remains space in biostatistics for a test that is straightforward to im-
plement, functional with a small number of historical control groups, and effectively
addresses the concern of bias that accompanies the use of historical data. The avail-
ability of such a test would allow for the reuse of data, thereby cutting the cost
of patient enrollment, reducing the burden of analysis, and accelerating the pace of
clinical trials.
Pocock’s test is an established and straightforward approach to using historical
data in clinical trials, but as it is framed by Pocock, is viewed as ”informal and
subjective” (Neuenschwander et. al.). To increase its appeal and practicality, methods
are presented in this thesis that increase its objectivity and functionality, making the
following advancements towards that end:
1. verification that Pocock’s test works as theoretically proposed under the ideal
condition of knowing σ2γ;
2. provision of a heuristic argument that knowledge of the bias γ might be as
effective as knowing σ2γ when applying Pocock’s test;
3. empirical demonstration that knowledge of the bias γ is sufficient to maintain
Type I Error and efficient in obtaining designed power;
4. provision of a method that effectively powers a trial when applying Pocock’s
test with apriori knowledge of σ2γ;
5. provision of an adaptive design that re-powers a trial using the estimated bias
at an interim look at the data;
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6. suggestion of experimental methods that use an estimate of bias to quantita-
tively specify σ2γ in the case of a single historical control group;
7. suggestion of experimental methods that quantitatively specify σ2γ when multi-
ple historical control groups are available.
6.1 Limitations
While progress has been made towards further formalizing Pocock’s test and gen-
erating objective ways to specify σ2γ, there are limitations to the methods presented.
First, built into these methods are the assumptions that the mean bias of the historical
control groups is 0, that the variables are all assumed to be normally distributed, and
that all groups have the same variance. From the analysis presented, it is not clear
these methods are robust to deviations from these assumptions. Second, the more
realistic methods proposed, in terms of practice, either have moderately inflated Type
I Error or lack significant power. Further investigation is necessary to find practical
methods that provide substantial power while maintaining nominal Type I Error.
Third, assessment of the methods was empirical. While care was taken to main-
tain generality and provide a wide spectrum of possibilities, Type I Error and power
measurements are ultimately specific to the conditions of the simulations presented.
6.2 Conclusions
The examination, exploration, and expansion of Pocock’s test has demonstrated
the significant challenge in maintaining Type I Error while at the same time providing
significant gains in power when using historical data in clinical trials. Progress has
been made towards increasing the objectivity and practicality of Pocock’s test, but
the methods developed still must be applied judiciously and in a more informal setting
than an FDA submission. Further research is required to improve upon these methods
presented before the Pocock’s test should be used in a formal submission to the FDA.
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Appendix A: Multiple Historical Control Groups Simulation Results
Table A.1: Type I Error nT = 100, nR = 50, nH = 50, δ = .352
Simulated σ2γ k nHk σˆ
2
γ1 σˆ
2
γ2 σˆ
2
γ3 σˆ
2
γ4 σˆ
2
γ5
0 2 25 0.0507 0.04535 0.0507 0.05435 0.05436
3 16 0.05134 0.04481 0.05134 0.05368 0.05378
4 12 0.05106 0.04433 0.05106 0.05355 0.05362
5 10 0.05055 0.04486 0.05055 0.0542 0.05399
0.01 2 25 0.04917 0.04815 0.05165 0.05593 0.05588
3 16 0.04793 0.04571 0.05134 0.05463 0.05443
4 12 0.04719 0.04525 0.0511 0.05433 0.05428
5 10 0.04617 0.04504 0.05087 0.05443 0.05417
0.04 2 25 0.04854 0.05376 0.05188 0.05852 0.05809
3 16 0.04672 0.04805 0.05153 0.05657 0.05592
4 12 0.04565 0.04661 0.0512 0.05621 0.05539
5 10 0.0449 0.04604 0.05052 0.05592 0.0552
0.16 2 25 0.04928 0.06526 0.05153 0.0617 0.06013
3 16 0.04768 0.053 0.0512 0.06035 0.05812
4 12 0.04725 0.04978 0.05103 0.0598 0.05722
5 10 0.04677 0.0488 0.05112 0.05931 0.05645
0.64 2 25 0.04999 0.07895 0.05143 0.06227 0.05612
3 16 0.04944 0.05694 0.0513 0.06238 0.05433
4 12 0.04955 0.05214 0.05138 0.06204 0.05347
5 10 0.04987 0.05086 0.05098 0.06213 0.05225
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Table A.2: Type I Error nT = 100, nR = 75, nH = 50, δ = .352
Simulated σ2γ k nHk σˆ
2
γ1 σˆ
2
γ2 σˆ
2
γ3 σˆ
2
γ4 σˆ
2
γ5
0 2 25 0.05098 0.04747 0.05098 0.05382 0.05384
3 16 0.05177 0.04752 0.05177 0.05367 0.05392
4 12 0.05112 0.04699 0.05112 0.05381 0.05379
5 10 0.05138 0.047 0.05138 0.05392 0.05397
0.01 2 25 0.04987 0.04938 0.05137 0.0548 0.05469
3 16 0.04975 0.04826 0.05232 0.05453 0.05428
4 12 0.04868 0.04746 0.05086 0.0543 0.05407
5 10 0.04855 0.04726 0.05158 0.0545 0.05434
0.04 2 25 0.04938 0.05299 0.05165 0.05631 0.05584
3 16 0.04881 0.04978 0.05205 0.05571 0.05532
4 12 0.04719 0.04867 0.05068 0.05494 0.05432
5 10 0.04715 0.04816 0.05091 0.05504 0.05438
0.16 2 25 0.04989 0.06074 0.05156 0.0584 0.05667
3 16 0.04944 0.05244 0.05166 0.05751 0.0556
4 12 0.04922 0.05082 0.05058 0.05693 0.05467
5 10 0.04882 0.04988 0.05087 0.05711 0.05461
0.64 2 25 0.05047 0.07206 0.05173 0.05799 0.05246
3 16 0.05028 0.05502 0.05127 0.05768 0.05072
4 12 0.05041 0.05188 0.05071 0.0578 0.04988
5 10 0.05027 0.05096 0.0503 0.05776 0.04945
Table A.3: Type I Error nT = 200, nR = 100, nH = 100, δ = .249
Simulated σ2γ k nHk σˆ
2
γ1 σˆ
2
γ2 σˆ
2
γ3 σˆ
2
γ4 σˆ
2
γ5
0 2 50 0.05181 0.04597 0.05181 0.05423 0.05421
3 33 0.05127 0.04421 0.05127 0.05427 0.05418
4 25 0.05087 0.04418 0.05087 0.0541 0.05414
5 20 0.05082 0.04411 0.05082 0.05376 0.05384
0.1 2 50 0.04814 0.0498 0.05078 0.05648 0.05643
3 33 0.04605 0.04615 0.05075 0.05523 0.05508
4 25 0.04544 0.04512 0.05107 0.05532 0.05511
5 20 0.04489 0.04457 0.05056 0.05489 0.0548
0.2 2 50 0.04835 0.05866 0.05107 0.05938 0.05894
3 33 0.04655 0.04982 0.05076 0.05798 0.05753
4 25 0.0456 0.04692 0.05107 0.05743 0.05668
5 20 0.04524 0.04691 0.05062 0.05718 0.05654
0.4 2 50 0.04971 0.07274 0.05202 0.0623 0.06069
3 33 0.04868 0.05424 0.05082 0.06176 0.05934
4 25 0.04839 0.05048 0.05109 0.06139 0.05864
5 20 0.04821 0.04972 0.05029 0.06075 0.058
0.8 2 50 0.05024 0.08382 0.05175 0.06118 0.05538
3 33 0.04986 0.05645 0.05102 0.06071 0.05308
4 25 0.05005 0.05181 0.0511 0.06158 0.053
5 20 0.05007 0.05089 0.05086 0.06191 0.05204
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Table A.4: Type I Error nT = 200, nR = 150, nH = 100, δ = .249
Simulated σ2γ k nHk σˆ
2
γ1 σˆ
2
γ2 σˆ
2
γ3 σˆ
2
γ4 σˆ
2
γ5
0 2 50 0.05038 0.04641 0.05038 0.05252 0.05252
3 33 0.05032 0.04604 0.05032 0.05206 0.05195
4 25 0.05044 0.04528 0.05044 0.05211 0.05213
5 20 0.04971 0.04607 0.04971 0.05197 0.05198
0.1 2 50 0.04868 0.04989 0.05081 0.05441 0.05428
3 33 0.04738 0.04702 0.04982 0.05334 0.05326
4 25 0.04681 0.0462 0.04989 0.05313 0.05291
5 20 0.04607 0.04662 0.0502 0.05284 0.05285
0.2 2 50 0.04831 0.05557 0.05066 0.05687 0.05639
3 33 0.04709 0.04915 0.05005 0.05531 0.05476
4 25 0.04661 0.04735 0.05024 0.05532 0.05475
5 20 0.04674 0.04765 0.05007 0.05468 0.05409
0.4 2 50 0.04915 0.06627 0.0508 0.05747 0.05589
3 33 0.04834 0.0526 0.05002 0.05736 0.05533
4 25 0.04808 0.0496 0.05026 0.05727 0.05494
5 20 0.04829 0.04933 0.04968 0.05666 0.05431
0.8 2 50 0.04938 0.07617 0.05029 0.05592 0.05043
3 33 0.04931 0.05445 0.05023 0.05654 0.04945
4 25 0.04895 0.05073 0.05003 0.05691 0.04841
5 20 0.05007 0.05089 0.05086 0.06191 0.05204
Table A.5: Type I Error nT = 500, nR = 250, nH = 250, δ = .249
Simulated σ2γ k nHk σˆ
2
γ1 σˆ
2
γ2 σˆ
2
γ3 σˆ
2
γ4 σˆ
2
γ5
0 2 125 0.05043 0.04449 0.05043 0.0528 0.05282
3 83 0.05069 0.04341 0.05069 0.05288 0.05278
4 62 0.05068 0.04337 0.05068 0.05286 0.0529
5 50 0.05065 0.04351 0.05065 0.0531 0.05316
0.1 2 125 0.0466 0.05356 0.04981 0.05796 0.05779
3 83 0.04572 0.04738 0.05042 0.05635 0.05623
4 62 0.04453 0.04605 0.05047 0.05596 0.05578
5 50 0.0444 0.04549 0.0504 0.05562 0.05549
0.2 2 125 0.04773 0.0659 0.04981 0.06116 0.06066
3 83 0.04666 0.05191 0.05004 0.06034 0.05965
4 62 0.04655 0.049 0.05028 0.05931 0.05854
5 50 0.04676 0.04802 0.05008 0.05894 0.05828
0.4 2 125 0.04889 0.07971 0.05002 0.06035 0.05878
3 83 0.049 0.05596 0.05006 0.06098 0.05873
4 62 0.04899 0.05113 0.04982 0.06143 0.05867
5 50 0.0489 0.0499 0.05023 0.06131 0.05852
0.8 2 125 0.04981 0.08379 0.04997 0.0571 0.05148
3 83 0.04966 0.05635 0.05022 0.0585 0.05085
4 62 0.04966 0.05142 0.05007 0.05928 0.05043
5 50 0.04984 0.05034 0.05009 0.05926 0.04946
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Table A.6: Type I Error nT = 500, nR = 375, nH = 250, δ = .249
Simulated σ2γ k nHk σˆ
2
γ1 σˆ
2
γ2 σˆ
2
γ3 σˆ
2
γ4 σˆ
2
γ5
0 2 125 0.0503 0.04685 0.0503 0.05203 0.052
3 83 0.05085 0.04666 0.05085 0.05243 0.05242
4 62 0.05111 0.04593 0.05111 0.0524 0.05238
5 50 0.05063 0.0461 0.05063 0.0524 0.05238
0.1 2 125 0.04812 0.05277 0.05017 0.05482 0.05472
3 83 0.0473 0.04868 0.05017 0.05392 0.05389
4 62 0.04708 0.04769 0.05069 0.05396 0.05387
5 50 0.04638 0.04704 0.05043 0.05373 0.05353
0.2 2 125 0.04822 0.06091 0.04972 0.05635 0.05592
3 83 0.04762 0.05143 0.04944 0.05547 0.05507
4 62 0.04781 0.04957 0.04996 0.05579 0.05529
5 50 0.04756 0.04846 0.05012 0.05571 0.05514
0.4 2 125 0.04912 0.07192 0.04951 0.05587 0.05425
3 83 0.04893 0.05369 0.0494 0.05567 0.05394
4 62 0.0492 0.05052 0.04971 0.05659 0.05449
5 50 0.04908 0.04983 0.04952 0.05654 0.05442
0.8 2 125 0.04983 0.07721 0.04995 0.05388 0.04882
3 83 0.04977 0.05435 0.04952 0.05447 0.04755
4 62 0.04984 0.05072 0.0496 0.05496 0.04699
5 50 0.04985 0.05026 0.0497 0.05522 0.04683
Table A.7: Power nT = 100, nR = 50, nH = 50, δ = .352
Simulated σ2γ k nHk σˆ
2
γ1 σˆ
2
γ2 σˆ
2
γ3 σˆ
2
γ4 σˆ
2
γ5
0 2 25 0.80103 0.75322 0.80103 0.74394 0.74397
3 16 0.79701 0.72985 0.79701 0.74131 0.74119
4 12 0.79709 0.71684 0.79709 0.74225 0.74239
5 10 0.80169 0.70913 0.80169 0.74429 0.74397
0.01 2 25 0.77531 0.74412 0.78493 0.73924 0.73894
3 16 0.77185 0.72423 0.78521 0.73861 0.73809
4 12 0.77261 0.71237 0.78781 0.73877 0.73852
5 10 0.77584 0.70546 0.79377 0.74212 0.74148
0.04 2 25 0.74031 0.72572 0.76156 0.72871 0.72766
3 16 0.73593 0.71211 0.76616 0.73106 0.7295
4 12 0.73585 0.70275 0.77191 0.73334 0.73181
5 10 0.73559 0.69705 0.77882 0.73721 0.73519
0.16 2 25 0.70102 0.69412 0.72929 0.70825 0.70317
3 16 0.69531 0.68922 0.73727 0.71395 0.70747
4 12 0.69153 0.68359 0.74326 0.71792 0.711
5 10 0.69002 0.68046 0.75205 0.72236 0.71456
0.64 2 25 0.67406 0.66351 0.69909 0.68681 0.66607
3 16 0.66932 0.66742 0.7065 0.69154 0.66424
4 12 0.6673 0.66615 0.7117 0.69575 0.66644
5 10 0.66632 0.66561 0.71832 0.70063 0.66932
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Table A.8: Power nT = 100, nR = 75, nH = 50, δ = .352
Simulated σ2γ k nHk σˆ
2
γ1 σˆ
2
γ2 σˆ
2
γ3 σˆ
2
γ4 σˆ
2
γ5
0 2 25 0.83518 0.80533 0.83518 0.80173 0.80171
3 16 0.83264 0.79299 0.83264 0.79968 0.7998
4 12 0.83271 0.78526 0.83271 0.79952 0.79957
5 10 0.83571 0.78006 0.83571 0.80119 0.80122
0.01 2 25 0.81864 0.80023 0.82467 0.79852 0.79835
3 16 0.81649 0.78932 0.8244 0.79729 0.79678
4 12 0.81743 0.78239 0.82649 0.79799 0.79776
5 10 0.81984 0.77776 0.83031 0.79999 0.7998
0.04 2 25 0.7976 0.78931 0.81015 0.79142 0.79058
3 16 0.79507 0.78101 0.8131 0.79246 0.79145
4 12 0.79545 0.77584 0.81634 0.79394 0.79272
5 10 0.79503 0.77368 0.82108 0.7962 0.79488
0.16 2 25 0.77454 0.76788 0.79108 0.77763 0.77377
3 16 0.77095 0.76676 0.79419 0.78095 0.77598
4 12 0.76925 0.76459 0.7998 0.78441 0.77864
5 10 0.76909 0.76338 0.8047 0.78695 0.78126
0.64 2 25 0.75892 0.74521 0.77338 0.76405 0.7472
3 16 0.75615 0.75304 0.77684 0.76703 0.74566
4 12 0.75459 0.75335 0.78087 0.77031 0.7464
5 10 0.75398 0.75353 0.78481 0.77297 0.74627
Table A.9: Power nT = 200, nR = 100, nH = 100, δ = .249
Simulated σ2γ k nHk σˆ
2
γ1 σˆ
2
γ2 σˆ
2
γ3 σˆ
2
γ4 σˆ
2
γ5
0 2 50 0.80046 0.75228 0.80046 0.74371 0.74372
3 33 0.79876 0.73133 0.79876 0.7434 0.74325
4 25 0.7998 0.71715 0.7998 0.74349 0.74345
5 20 0.79981 0.70709 0.79981 0.74432 0.74444
0.1 2 50 0.75934 0.73706 0.77429 0.73452 0.73425
3 33 0.75736 0.7206 0.77888 0.73689 0.73646
4 25 0.75776 0.70961 0.78307 0.73886 0.73844
5 20 0.75659 0.70122 0.78501 0.73956 0.73903
0.2 2 50 0.72022 0.71214 0.74512 0.72029 0.71902
3 33 0.71487 0.70068 0.7526 0.72455 0.72278
4 25 0.71315 0.69488 0.76011 0.72811 0.72629
5 20 0.71093 0.6888 0.76408 0.73064 0.7286
0.4 2 50 0.68518 0.67712 0.71311 0.69676 0.69173
3 33 0.67961 0.67517 0.72134 0.7039 0.69691
4 25 0.67731 0.67332 0.72942 0.70834 0.70118
5 20 0.675 0.67083 0.73412 0.71185 0.70415
0.8 2 50 0.66599 0.65436 0.68748 0.67733 0.65561
3 33 0.66158 0.65982 0.69418 0.68243 0.65471
4 25 0.66012 0.65939 0.69949 0.68607 0.65467
5 20 0.65908 0.65873 0.70352 0.68977 0.65661
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Table A.10: Power nT = 200, nR = 150, nH = 100, δ = .249
Simulated σ2γ k nHk σˆ
2
γ1 σˆ
2
γ2 σˆ
2
γ3 σˆ
2
γ4 σˆ
2
γ5
0 2 50 0.83702 0.80686 0.83702 0.80245 0.80251
3 33 0.83531 0.79407 0.83531 0.80217 0.80209
4 25 0.83705 0.78582 0.83705 0.80247 0.80241
5 20 0.83621 0.78057 0.83621 0.8022 0.80205
0.1 2 50 0.80966 0.7963 0.81929 0.79605 0.79588
3 33 0.80961 0.78703 0.8226 0.79754 0.79731
4 25 0.81075 0.78092 0.82657 0.79926 0.79886
5 20 0.80972 0.77635 0.82673 0.79948 0.79902
0.2 2 50 0.78663 0.77992 0.80174 0.78575 0.78489
3 33 0.7838 0.7752 0.80641 0.78916 0.78795
4 25 0.78373 0.7723 0.81272 0.79271 0.79145
5 20 0.78282 0.76923 0.81444 0.79393 0.7922
0.4 2 50 0.76706 0.7558 0.78288 0.77204 0.76766
3 33 0.76325 0.75945 0.78763 0.77522 0.77016
4 25 0.76194 0.75943 0.79366 0.77976 0.77392
5 20 0.76102 0.75873 0.79527 0.78137 0.77481
0.8 2 50 0.75545 0.73871 0.76811 0.76001 0.74225
3 33 0.75309 0.74982 0.77141 0.76313 0.74114
4 25 0.75181 0.75096 0.77558 0.76563 0.74069
5 20 0.75144 0.75133 0.77731 0.76717 0.74118
Table A.11: Power nT = 500, nR = 250, nH = 250, δ = .249
Simulated σ2γ k nHk σˆ
2
γ1 σˆ
2
γ2 σˆ
2
γ3 σˆ
2
γ4 σˆ
2
γ5
0 2 125 0.80012 0.75266 0.80012 0.74339 0.74343
3 83 0.8005 0.73181 0.8005 0.74288 0.74283
4 62 0.79928 0.71705 0.79928 0.7421 0.7421
5 50 0.80082 0.70715 0.80082 0.74313 0.74315
0.1 2 125 0.73284 0.72197 0.75533 0.72589 0.72559
3 83 0.7305 0.70943 0.76551 0.7305 0.73004
4 62 0.72858 0.70043 0.77002 0.73269 0.73236
5 50 0.72779 0.69441 0.77507 0.73417 0.73367
0.2 2 125 0.69527 0.68832 0.72279 0.70461 0.70338
3 83 0.68931 0.68424 0.73443 0.71159 0.71006
4 62 0.68671 0.68083 0.74063 0.71621 0.71433
5 50 0.6848 0.67714 0.74637 0.71927 0.71747
0.4 2 125 0.67044 0.65976 0.69474 0.68282 0.67719
3 83 0.66558 0.66261 0.70304 0.68884 0.68164
4 62 0.66365 0.66279 0.70951 0.69362 0.68601
5 50 0.66238 0.66174 0.7139 0.69627 0.68792
0.8 2 125 0.65893 0.64563 0.67591 0.66901 0.64659
3 83 0.65571 0.65381 0.68009 0.67154 0.64222
4 62 0.65518 0.65473 0.68563 0.67505 0.64351
5 50 0.65485 0.65503 0.68867 0.67727 0.64314
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Table A.12: Power nT = 500, nR = 375, nH = 250, δ = .249
Simulated σ2γ k nHk σˆ
2
γ1 σˆ
2
γ2 σˆ
2
γ3 σˆ
2
γ4 σˆ
2
γ5
0 2 125 0.83482 0.80575 0.83482 0.80178 0.80173
3 83 0.83593 0.79441 0.83593 0.80251 0.80246
4 62 0.8347 0.7862 0.8347 0.80101 0.80106
5 50 0.83498 0.78013 0.83498 0.80185 0.80188
0.1 2 125 0.79331 0.78642 0.80653 0.78979 0.78959
3 83 0.79261 0.77974 0.81264 0.79283 0.79251
4 62 0.79164 0.77559 0.81615 0.79464 0.79429
5 50 0.7913 0.77209 0.81963 0.7965 0.79613
0.2 2 125 0.77154 0.76341 0.78755 0.77626 0.77523
3 83 0.76878 0.76436 0.79381 0.78065 0.77933
4 62 0.76735 0.76302 0.79803 0.78325 0.78193
5 50 0.76619 0.76204 0.80183 0.78624 0.78438
0.4 2 125 0.75756 0.74306 0.77164 0.7635 0.75903
3 83 0.75463 0.75122 0.7754 0.76637 0.76055
4 62 0.75387 0.75294 0.77971 0.76968 0.7634
5 50 0.75343 0.75293 0.78258 0.77187 0.76524
0.8 2 125 0.75177 0.7326 0.7614 0.75579 0.7383
3 83 0.74971 0.7465 0.76272 0.75678 0.73374
4 62 0.74958 0.74895 0.76611 0.75895 0.73336
5 50 0.74914 0.7489 0.76736 0.75983 0.7325
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